

07. 26. 00

PATENT

Attorney Docket No. DECLE18.001C1

Date: July 24, 2000

Page 1

670529/60
09 JUL 2000
07/24/00

07/24/00
1-3693 U.S. PTO

ASSISTANT COMMISSIONER FOR PATENTS

WASHINGTON, D.C. 20231

ATTENTION: BOX PATENT APPLICATION

Sir:

Transmitted herewith for filing is the patent application of

Inventors: **Reinhilde Schoonjans, Nico Mertens, Walter Fiers, Roland Contreras**

For: **MULTIPURPOSE ANTIBODY DERIVATIVES**

Enclosed are:

- (X) 14 sheets of drawings.
- (X) Sequence Listing in 13 pages.
- (X) Recordation form cover sheet with 2-page assignment.
- (X) A verified statement to establish small entity status under 37 CFR 1.9 and 37 CFR 1.27.
- (X) Initial signed declaration by inventor(s).
- (X) Return prepaid postcard.

(X) **PRELIMINARY AMENDMENT**

Please amend the application to state the following prior to the first: --This application is a continuation of prior application PCT/EP99/00477.--

The filing fee is calculated below for a small entity:

CLAIMS AS FILED				
FOR	NUMBER FILED	NUMBER EXTRA	RATE	FEE
Basic Fee			\$345	\$345
Total Claims	42 - 20 =	22 x	\$9	\$198
Independent Claims	4 - 3 =	1 x	\$39	\$39
TOTAL FILING FEE		\$582		

- (X) A check in the amount of \$582 to cover the filing fee is enclosed.
- (X) A check in the amount of \$40 to cover the assignment recording fee.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, now or in the future, or credit any overpayment to Account No. 11-1410. A duplicate copy of this sheet is enclosed.

INTELLECTUAL PROPERTY LAW
KNOBBE, MARTENS, OLSON & BEAR

A LIMITED LIABILITY PARTNERSHIP INCLUDING
PROFESSIONAL CORPORATIONS

PATENT, TRADEMARK AND COPYRIGHT CAUSES

620 NEWPORT CENTER DRIVE

SIXTEENTH FLOOR

NEWPORT BEACH, CALIFORNIA 92660-8016

(949) 760-0404

FAX (949) 760-9502

INTERNET WWW.KNOB.BE

JOSEPH S. CANTFRANI
JOSEPH M. REISMAN, PH.D.
WILLIAM R. ZIMMERMAN
GLEN L. RUTLAND

ERIC S. FURMAN, PH.D.

TIZAH ABE LOWE

GEORREY T. HDA

ALEXANDER S. FRANCO

SANJIVPA S. GILL

SUSAN M. MOSS

JAMES W. HILL, M.D.

ROSE M. THIESSEN, PH.D.

MICHAEL L. FULLER

MICHAEL A. GULLIANA

MARK J. KERTZ

RABINDER N. NARULA

BRUCE S. ITCHAKWITZ, PH.D.

PETER M. WIGLEY

THOMAS S. MCCLENNAHAN

MICHAEL S. OKAMOTO

JOHN M. GROVER

MALLARY K. DE MERLIER

IRFAN A. LATIF

AMY C. CHRISTENSEN

SHARON S. NG

MARK J. GALLAGHER, PH.D.

DAVID G. JANKOWSKI, PH.D.

BRAN C. HORNE

PATSYON J. LEMELLEUR

WILLIAM W. BERRY

DIANA W. PRINCE

OF COUNSEL

JERRY R. SEILER

PAUL C. STEINHAUT

JAPANESE PATENT ATTY

KATSUHIRO ARAI**

EUROPEAN PATENT ATTY

MARTIN HELLEBRANDT

KOREAN PATENT ATTY

MINCHEOL KIM

SCIENTISTS & ENGINEERS

(NON-LAWYERS)

RAMOND J. SALENIEKS**

NEIL S. BARTLETT, PH.D.**

DANIEL E. JOHNSON, PH.D.**

JEFFREY KOEPEK, PH.D.**

KHURRAM RAHMAN, PH.D.

JENNIFER A. HAYNES, PH.D.

BOENAN P. O'NEILL, PH.D.

THOMAS Y. NAGATA

LINDA H. LIU

FASHHART WAISHNAV, PH.D.

MEGUMI TANAKA

CHE S. CHENESKIN, PH.D.**

ERIK W. ASCHEB-E

PHILIP C. HARTSTEIN

JULIE A. HODDER

CHRIS S. CASTLE

JAMES W. AUSLEY

R. P. CARON, PH.D.

JENNIFER HAYES

KIRK C. PASTORIAN, PH.D.

CHARLES T. BIGGEL

KEITH R. MCCOLLUM

LANG S. MCHARY

* A PROFESSIONAL CORPORATION

** U.S. PATENT AGENT

Assistant Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Attorney Docket No. : DECLE18.001C1

Applicants : Schoonjans et al.

For : MULTIPURPOSE ANTIBODY
DERIVATIVES

Attorney : Daniel E. Altman

"Express Mail"


Mailing Label No. : EL559437832

Date of Deposit : July 24, 2000

I hereby certify that the accompanying

Transmittal in Duplicate; Specification in 62 pages; 14 sheets of drawings;
Sequence Listing in 13 pages; **SIGNED** Declaration by Inventor in 2 pages;
Recordation Form Cover Sheet and Assignment in 2 pages; Small Entity
Statement; Check for Filing Fee; Check for Assignment; Return Prepaid Postcard

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and are addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.


Sylvia Gaston

H:\DOCS\UAHJAH-2986.DOC:bb\072400

Applicant: Schoonjans
Application No.: Pending
Filed: Filed Herewith
For: **MULTIPURPOSE ANTIBODY DERIVATIVES**

Attorney's Docket No.: DECLE18.001C
Page 1

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL-ENTITY STATUS

I, the undersigned, do hereby declare that:

☒ I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION: Vlaams Interuniversitair Instituut Voor Biotechnologie
ADDRESS OF ORGANIZATION: Rijvisschestraat 120, B-9052 Zwijnaarde, Belgium
TYPE OF ORGANIZATION: University

☒ University or other institution of higher education.

I further declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.9(e) for purposes of paying reduced fees to the United States Patent and Trademark Office regarding the invention described in the patent or application identified above.

The individual, concern or organization identified above has not assigned, granted, conveyed or licensed, and is under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

If the rights held by the above-identified individual, concern or organization are not exclusive, each individual, concern or organization having rights in the invention are identified below. Each such individual, concern or organization must file separate verified statements averring to their status as small entities.

***NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27).**

FULL NAME:

ADDRESS:

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small-entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Rudy Dekeyser

Vice General Director

NAME OF PERSON SIGNING:

TITLE OF PERSON (if not an owner or individual):

ADDRESS OF PERSON SIGNING: Rijvisschestraat 120, B-9120 Zwijnaarde, Belgium

SIGNATURE:

H:\DOCS\JAHJAH-2900.DOC:bb
070600

DATE: July 14, 2000

MULTIPURPOSE ANTIBODY DERIVATIVES

TECHNICAL FIELD

The present invention relates to a class of molecules specified as novel multipurpose antibody derivatives. The invention further relates in particular to such antibody derivatives that have two or more

5 antigen binding parts, derivatives that have at least two antigen binding parts, combined with at least one other function, such as a toxin, an enzyme, a cytokine, a hormone or a signalling molecule, and derivatives that have an antigen binding part, combined with at least two

10 other functions.

BACKGROUND OF THE INVENTION

Due to their versatility, multipurpose antibody derivatives (mpAbs), such as bispecific antibodies

15 (BsAb), immunotoxins and bifunctional antibodies are promising tools in the treatment of various (human) diseases. The first arm usually allows to specifically recognize a target cell (e.g. cancer cell) by means of an antigen binding function, while another determinant may

20 be directed through an antigen binding function towards a second cell type (e.g. a cytotoxic T cell), or it may be a toxin, an enzyme (e.g. to locally cleave and activate a prodrug), a cytokine, a hormone or a signalling molecule.

The difficulty of producing functional BsAb in

25 sufficient quantity and purity is still hampering the more general use of BsAb in clinical applications. When using the quadroma technology only 10% of the immunoglobulin pool is the correct, bispecific antibody. Therefore, time consuming and costly purification

30 procedures are inevitable.

Chemical reassociation of antibody fragments suffers from loss of affinity by protein denaturation or unorthodox disulphide bond formation, as well as from the use of a chemical cross-linker, generating inactive,

35 chemically modified structures.

Both these classical methods producing BsAb give rather low yields. Recombinant DNA methodology and

antibody engineering has greatly facilitated the production of antibody derivatives in heterologous expression systems. By genetic fusion of various antibody fragments to generate BsAb, the normal tetrameric antibody structure $(H+L)_2$ is reduced. When the total Fc-portion is included, the self-association of the disulphide bridges in the hinge region reduces considerably the yield of heterodimeric BsAb. Hence purification away from bivalent, homodimeric by-products is still required. In order to improve the level of heterodimeric, bispecific product, a "Knobs-into-holes" principle has been developed to engineer the CH3 domains in the Fc-tail for preferential heterodimerization. The molecule proposed by Ridgway et al. (1996) comprises a complete Fc portion, which increases the molecular weight of the final protein beyond the optimal size for biodistribution. Furthermore, the Fc portion can interact with a multitude of Fc receptors present on various cells in the body, which can deviate the binding of this molecule to aspecific targets.

Small antibody-derivatives (such as sFv, bssFv, diabodies) have the advantage of easy penetration in solid tumors; moreover, partly because of the absence of high disulphide containing hinge regions, they can be produced in high amounts in heterologous expression systems. However, due to their small size, these molecules are generally cleared too rapidly from the circulation to allow efficient accumulation at the tumor site, while molecules of intermediate size have improved serum stability and retain satisfactory tissue penetration.

In order to achieve medium sized heterodimers, sFv have been linked by incorporating an additional peptide, leucine zippers, amphiphatic helices or streptavidin. These heterodimerization extensions, however, might be immunogenic.

Similar problems are encountered in the preparation of immunotoxins and antibody derivatives

having an enzymatic function. Monovalent single chain Fv fragments (sFv) or disulfide stabilized Fv fragments (dsFv) are predominantly used to construct toxin fusions. This results in weaker binding and poor internalization
5 due to the monovalent binding, and rapid blood clearance due to the small molecule size.

DISCLOSURE OF INVENTION

In view of the above it is the object of the
10 present invention to provide a class of molecules, specified as novel multipurpose antibody derivatives that can be efficiently prepared without many by-products, that have an intermediate size and that combine two or more antigenic binding sites, or one antigenic binding
15 site with two or more other functions in one molecule.

This is achieved according to the invention by multipurpose antibody derivative, comprising the CL and VL domains of a first antibody with a desired first antigen binding specificity, the CH1 and VH domains of
20 the said first antibody interacting with the CL and VL domains, and one or more other molecules having at least one further purpose coupled to one or more of the domains of the first antibody.

The invention is based on the potential of the
25 specific VL-CL:VH-CH1 (referred to as "L:Fd") interaction to drive disulphide-stabilized heterodimerization of recombinant antibody-derived fusion proteins. The use of the L:Fd interaction which can be both natural or chimeric to drive heterodimerization has several
30 advantages. First of all, their natural heterodimeric interaction circumvents the need for protein engineering to achieve complementarity. Furthermore, the interaction is very strong, in contrast to L:L homodimers which are only poorly formed or Fd:Fd homodimers which were never
35 detected in eukaryotic expression systems. Also, in bacterial expression systems the Fd chain alone is aberrantly folded (Ward, 1992). Finally, a single,

0055343-072400

natural disulphide bridge stabilizes the L:Fd heterodimer.

Each of the two domains of the light and heavy chain can be extended with another molecule (e.g. VL or VH region, a sFv, a toxin, an enzyme such as a prodrug cleaving enzyme, a cytokine, a hormone, a signalling molecule, etc.).

Thus, the invention relates to a class of molecules specified herein as novel "multipurpose antibody derivatives". This class of molecules is created by heterodimerization of two constituting components. Heterodimerization is obtained by the specific heterotypic interaction of a chosen CH1-VH combination of immunoglobulin domains, with a chosen CL-VL combination of immunoglobulin domains. The VHCH1-VLCL interaction is proposed as a very efficient heterodimerization scaffold that could be efficiently produced. By choosing the appropriate VH and VL domains in the VHCH1 and VLCL context, a binding specificity can be constituted by the heterodimerization scaffold itself. One or both of the comprising VHCH1 and VLCL chains can thus be extended at either the N- or the C-terminus or both with other molecules, such as a toxin, an enzyme, a cytokine, a hormone or a signalling molecule and derivatives that have an antigen binding part for the purpose of combining these molecules with each other.

The construction of the Fab part of the antibody, fixed to relatively simple molecules such as bacterial alkaline phosphatase, or a truncated mutant form of Pseudomonas exotoxin has been described before (Ducancel et al., 1993, Choe et al., 1994). However, unexpectedly it was found according to the invention that the L:Fd interaction is still able to drive the heterodimerization when one of the chains of the Fab is fused to a complex molecule as a single-chain antibody fragment. Even more unexpectedly, it was found that also both chains of the Fab may be fused to other molecules,

without affecting the ability of the molecules to form preferentially heterodimers.

ScFv molecules consist of domains (VL and VH) of the same nature as can be found in the Fd and L chains, so wrongly formed non-functional derivatives could easily be expected. However, the findings as illustrated in the examples unexpectedly show that such molecules can be produced efficiently and is proven functional for all its components.

Surprisingly, this could be achieved with peptide linkers as short as a few amino acids. By excluding the hinge-region, dimerization of the Fab-scFv fusion is omitted. Homodimerization of some specificities might induce unwanted activating or inhibiting functions with effector cells. In order to avoid this, homodimerization through e.g. the hinge region can be avoided by excluding this region in the Fab-scFv molecule.

The other molecule(s) can be fused either to the C-terminus of the CH1, the N-terminus of the VH, the C-terminus of the CL and/or the N-terminus of the VL. In total, the invention offers 15 different variant types of combinations of other molecules with the L + Fd construct as a scaffold. The variant types are summarized in table 1. Each variant type can in turn be provided with various kinds of other molecules.

Table 1

No.	other molecule on C-terminus CH1	other molecule on N-terminus VH	other molecule on C-terminus CL	other molecule on N-terminus VL
1	+	-	-	-
2	-	+	-	-
3	-	-	+	-
4	-	-	-	+
5	+	+	-	-
6	-	+	+	-

5	7	-	-	+	+
	8	+	-	-	+
	9	+	-	+	-
	10	-	+	-	+
	11	+	+	+	-
	12	+	+	-	+
	13	+	-	+	+
	14	-	+	+	+
10	15	+	+	+	+

The L:Fd acts as a "carrier" for the other molecule. In the case of an sFv as the other molecule, the total size of the sFv is increased due to the presence of the carrier. As a consequence it will not have the disadvantage of known sFv's or bssFv that are cleared too rapidly from the circulation. The L and Fd chains can if desired, constitute a binding specificity of their own. In this case, the L and Fd chains contribute a function of their own, apart from serving as a heterodimerization signal.

When a molecule of the invention combines two (different or equal) functions, it is called bifunctional. Similarly, when a molecule of the invention combines three or more than three different or equal functions, it is called trifunctional, respectively multifunctional. When a molecule of the invention is combining two, three or more antibody parts having a different specificity, it is called bi-, respectively tri- or multispecific. When a molecule of the invention is combining two, three or more antibody parts having the same specificity, it is called bi-, respectively, tri- or multivalent for the binding specificity.

In a first preferred embodiment, the invention provides for a novel, recombinant mpAB that is a bispecific, bifunctional antibody (BsAb) when the specificities are different or bivalent, bifunctional

09625049 072400

5 the aforementioned criteria and incorporates preferential heterodimerization through its L:Fd domains.

10 fused to the N-terminus of VH or the N-terminus of VL. In
a third preferred embodiment, the invention provides for
a novel, recombinant bispecific, trifunctional or
bivalent, trifunctional mpAB that is an immunotoxin based
on the fusion of a BsAb or a BvAb according to the first
15 embodiment and a toxin, which is fused to the C-terminus
of the heavy chain of the Fab that does not carry the
sFv.

20 trifunctional or bivalent, trifunctional mpAB that is called a catalytic antibody (cAB) based on the fusion of a BsAb or a BvAb and an enzyme, which is fused to the C-terminus of the heavy chain of the Fab that does not carry the sFv.

25 According to a fifth preferred embodiment, the invention provides for a novel, recombinant bispecific, trifunctional or bivalent, trifunctional mpAB that is combined with a hormone, a cytokine or a signalling function by fusing of a molecule with said activity to an

30 BsAb or a BvAb according to the first embodiment.

According to a sixth preferred embodiment both the C-terminus of CH1 and the C-terminus of CL are fused to a sFv, resulting in a molecule with three antigen binding parts. This molecule is trifunctional, and can be 35 trivalent monospecific, bivalent bispecific or monovalent trispecific.

Thus, this invention offers inter alia the possibility to create bivalent trifunctional immunotoxins

(i.e. molecules that are intended for two purposes, namely bivalent antigen binding and toxicity) or trispecific (i.e. three antigen specificities), antibodies. In the latter case not only the CH1, but also the CL is extended with an sFv.

The other molecule can be linked to the L or Fd antibody part(s) directly or via a linker. The presence of a linker of at least 1, preferably more than 3 amino acids can be used to avoid steric hindrance between two or more antigen binding sites and between antigen binding site(s) and the active center of the other molecule. Linkers other than amino acid chains may also be used.

According to one specifically preferred embodiment of the invention various anti murine CD3 ϵ -single-chain fragments (sFv) were fused to the C-terminus of CH1 of an Fd fragment specific for human placental alkaline phosphatase (hPLAP). This Fab-sFv bispecific antibody derivative (of the general formula Fab-linker-sFv, wherein the linker is e.g. EPSG but can be variable in sequence and length) can be used to link cytotoxic cells to tumor cells.

The fusion product was further improved for reaching far apart antigens by providing a sufficiently long spacer sequence (of the general formula Fab-linker-sFv, wherein the linker is e.g. EPSGP(G₄S)₃M but can be variable in sequence and length). After eukaryotic secretion, specific heterodimerization between the corresponding anti-hPLAP light chain and the Fd fragment occurred, where the latter carried a functional sFv. Upon expression in mammalian cells more than 90% of the immunoglobulin material in the medium was the specific heterodimer, with only minor contamination of light chain derived homodimers and monomers, which did not show hPLAP binding capacity. Homodimers from the heavy chain derived VH-CH1 fused to the anti CD3 ϵ sFv were never observed.

The Fab-sFv fusion protein between the anti murine CD3 ϵ sFv and the anti-hPLAP-Fab here described is an example for the efficient production of specific,

disulphide stabilized heterodimers which can be used for making bispecific antibodies. The invention is not limited to this particular example. Other antigen binding specificities can be used and for the other purpose or
5 function there is also a variety of options. The invention lies in principle in the finding that the L:Fd interaction is highly specific and can be used as a heterodimeric scaffold to construct a new type of mAb. The VL and CL domains in the L chain, as well as the Vh
10 and CH1 domains in the Fd chain do not necessarily have to be derived from the same antibody.

The derivatives of the invention can be used in the treatment of tumors, in the treatment of various infected cells, in the treatment of autoimmune diseases
15 or thrombosis. Moreover the derivatives of the invention can be used to direct a virus towards immunological effector cells, to induce or resolve blood clotting, to eliminate specific cell types in vitro or in vivo, to establish or improve transfections, or in diagnosis.

20 The invention further relates to DNA constructs encoding the heavy chain domains of an antibody derivative of the invention, comprising suitable transcription and translation regulatory sequences operably linked to sequences encoding the VH and CH1
25 domains of the first antibody and optionally a coding sequence for the other molecule operably linked thereto.

In such a DNA construct the coding sequence for the other molecule may consist of DNA sequences encoding the VL and VH domains of a second antibody, which DNA
30 sequences are operably linked to each other in either one of the sequences 5'-VL2-VH2-3' or 5'-VH2-VL2-3'.

In the DNA construct a DNA sequence encoding a linker sequence may be incorporated between one or more of the VH, CH1, VL2 and/or VH2 coding sequences and/or
35 the coding sequence for the other molecule. The linker helps in avoiding steric hindrance between the various domains.

00422.402500

5 A particularly preferred DNA construct, designated as pCA2C11sFvE6Hf, is obtainable from E.coli DH5 α cells deposited on October 15, 1997 at the Belgian Coordinated Collection of Microorganisms and given the deposit accession no. LMBP3715. Another preferred DNA construct is designated as pCAE6HfGS2C11sFv (also identified as pCAE6H2sc2C11H) and obtainable from E.coli MC1061 cells deposited on October 15, 1997 at the Belgian Coordinated Collection of Microorganisms and given the
10 deposit accession no. LMBP3716.

Furthermore the invention relates to DNA construct encoding the light chain domains of an antibody derivative of the invention, comprising suitable transcription and translation regulatory sequences
15 operably linked to sequences encoding the VL and CL domains of the first antibody and optionally a coding sequence for the other molecule operably linked thereto. The coding sequence for the other molecule may consist of DNA sequences encoding the VL and VH domains of a second
20 antibody, which DNA sequences are operably linked to each other in either one of the sequences 5'-VL2-VH2-3' or 5'-VH2-VL2-3'.

Also in this DNA construct a linker sequence can be incorporated between one or more of the VL, CL,
25 VL2 and/or VH2 coding sequences and/or the coding sequence for the other molecule.

According to a further aspect the invention relates to a set of DNA constructs for producing multipurpose antibody derivatives of the invention,
30 comprising any one of the constructs described above together with a construct encoding at least the light domains VL and CL of the first antibody or together with a construct encoding at least the heavy domains VH and CH of the first antibody, depending on whether the other
35 construct encodes the heavy or light domains of the first antibody.

In a first embodiment the set consists of vector pCAE6H2sc2C11H and vector pCAG6SE6L. In an

004220 005550

alternative embodiment the set consists of vector pCA2C11sFvE6Hf and vector pCAG6SE6L. Those sets can be used for producing multipurpose antibody derivatives of the invention in heterologous expression host cells. The invention also relates to a method for producing multipurpose antibody derivatives, comprising expression of such a set in heterologous expression host cells. The host cells may be E.coli cells, other bacterial cells, such as Bacillus spp., Lactobacillus spp. or Lactococcus spp.; actinomycetes; yeasts; filamentous fungi; mammalian cells, such as COS-1 cells, HEK cells, insect cells, transgenic animals or plants.

Another aspect of the invention relates to a medical preparation, comprising multipurpose antibody derivatives.

A further aspect of the invention relates to the use of multipurpose antibody derivatives in diagnosis.

According to a final aspect the invention
20 relates to the use of multipurpose antibody derivatives
for the preparation of a medicament for the treatment of
cancer, infections, parasites, autoimmune diseases,
thrombosis.

The term "purpose" is used herein to indicate a
25 certain activity or other function, preferably antigen
binding specificity, toxicity, signalling or enzymatic
activity.

The term "derivative" is used herein to refer to molecules other than the classic antibodies consisting of two light chains and two heavy chains, which heavy chains in turn comprise multiple constant domains. The derivatives comprise at least one VL domain, one CL domain, one VH domain and one CH domain.

Derivatives of the present invention can thus
35 be prepared by genetic engineering using methods well
known in the art. In the examples that follow, it is
described how by genetic engineering, a new type of
bispecific antibody with potential use in immunotherapy

by redirected cellular cytotoxicity was designed. The design of the antibody was based on the very effective and selective heterodimerization of the two antibody-chains, L and Fd. Both the Fd and the L chain can be extended with new determinants, herein called "other molecules" (peptides, domains), either at their N-terminus or C-terminus or both. As an example the molecule Fab (L + Fd) is described extended either at the N-terminus or at the C-terminus of the Fd fragment with a single chain antibody fragment (sFv). The latter, Fab-(G₄S)₃-sFv, was characterized in detail. (G₄S)₃ is short for EPSGPGGGGSGGGGSGGGGSM. The bispecific species was the predominant product in a heterologous expression system. It had an intermediate molecular weight which is beneficial for serum stability, biodistribution and solid tissue penetration.

The following examples provide the teaching starting from which variants can be prepared. The examples are therefore in no way intended to be limiting the invention. In the examples "VH", "CH1", "CL" and "VL" are used for domains derived from the first antibody. "VH2" and "VL2" are used for domains derived from the second antibody. "VH3" and "VL3" are used for domains derived from the third antibody.

BRIEF DESCRIPTION OF THE FIGURES

In the examples reference is made to the following figures:

Figure 1: Diagram of the pSV51 (Huylebroeck *et al.*, 1988), pCAGGS (Niwa *et al.*, 1991) and pCDNA3.1zeo⁻ (Invitrogen, Carlsbad, CA, USA) expression vector inserts used for transfection. E6=parental anti hPLAP antibody, 2C11=derived from the 145-2C11 parental anti CD3 antibody, B1=parental anti BCL1 antibody, 3D5=parental anti (His)₅₋₆ antibody, VL and CL=variable domain and constant domain of the light chain, VH and CH1=variable and first constant domain of the heavy chain, Bla=Escherichia coli β -lactamase, mIL2=murine interleukin 2.

All light chain domains of E6 are in black, all heavy chain domains of E6 in white. 2C11scFv and 3D5scFv domains are hatched. B1scFv domains, Bla and mIL2 are in grey.

- 5 **Figure 2:** Heterodimerization of CL- and CH1 containing molecules in eukaryotic cells can be dependent on the pairing of appropriate VL and VH domains.

Figure 3: Expression of C-terminal Fab-scFv fusion proteins.

- 10 **Figure 4:** C-terminal Fab-scFv fusion proteins are functional as bispecific antibodies.

Figure 5: Chimeric L:Fd chains molecules can be used to heterodimerize Fab-scFv bispecific antibodies.

Figure 6: Expression, functionality

- 15 purification and serum stability of bispecific Fab-scFv molecules with Fab chains.

Figure 7: Fd:L can efficiently heterodimerize two different scFv molecules.

Figure 8: Functionality of the trispecific

- 20 antibody derivatives.

Figure 9: Expression of multivalent antibody derivatives.

Figure 10: Expression of multifunctional antibody derivatives.

25

EXAMPLES

MATERIALS AND METHODS

Preparation of constructs

- 30 **Bacterial strains and cell lines**

E. coli MC1061 (F^{araD139} Δ(ara-leu)7696 galE15 galK16 Δ(lac)X74 rpsL (Str^r) hsdR2(r_k⁻m_k⁺) mcrA mcrB1 and DH5α (endA1 hsdR17 (r_k⁻m_k⁺) supE44 thi-1 recA1 gyrA (Nal^r) relA1 Δ(lacIZYA-argF)U169 deoR (#80dlacΔ(lacZ)M15)) were
35 used for transformations and DNA isolations. The bacteria were grown in LB medium, supplemented with 100 μg/ml triacillin. The COS-1 cell line, derived from monkey CV-1 kidney cells, was used for eukaryotic expression.

- HEK293T, a human embryonic kidney cell line transfected with SV40 large T-antigen (SV40T tsA1609) (DuBridge et al., 1987) was used for eukaryotic expression. TE₂ cells are murine, CD3 positive "T helper"-1 cells (Grooten et al., 1989), and were cultured in RPMI1640 medium (GibcoBRL life technologies, Paisly, UK) supplemented with 30 U/ml recombinant murine IL2, 0.06 mM BME, 10% FCS, 0.03% L-glutamine, 100 U/ml penicillin, 100 mg/l streptomycin and 0.4 mM sodium pyruvate. Mouse fibrosarcoma derived MO₄ cells were cultured in REGA-3 medium (GibcoBRL) supplemented with 10% FCS, 0.03% L-glutamine, 100 U/ml penicillin, 100 mg/l streptomycin and 0.4 mM sodium pyruvate. MO₄I₄ (hPLAP⁺) cells are MO₄ cells transfected with the hPLAP gene (Smans et al., 1995; Hendrix et al., 1991). BCL1^{vitre} cells (gift from Dr. Thielemans) were cultured as TE₂ cells but with IL2.

Plasmids and gene assembly

- Restriction enzymes were purchased from GibcoBRL life technologies (Paisly, UK), Vent DNA polymerase was from New England Biolabs (Beverly, MA, USA), T4 DNA ligase, Klenow enzyme and T4 DNA polymerase were from Boehringer Mannheim (Mannheim, Germany). All enzymes were used as recommended by the manufacturers.
- All primers for PCR amplification were purchased from GibcoBRL. DNA amplification was performed in a Biometra heat block using a predenaturing step of 10 min at 94°C, followed by 30 cycles, containing a denaturing step (94°C), an annealing step (55°C), and an extension step (72°C), each for 30 sec.

All expression modules are schematically represented in figure 1.

- The cloning of the light chain (L) and the truncated heavy chain fragment (Fd) of the parental murine anti hPLAP mAb E6 (IgG2b, κ) in the vectors pSV51E6L (LMBP2142) and pSV51E6Hf1 (LMBP2143), respectively, was described previously (De Sutter et al., 1992a).

pSVE6sFvE6CL

A single-chain fragment of the anti hPLAP VH and VL was cloned in the vector pSV51E6sFv (LMBP3609, unpublished and provided by S. Dincq and K. De Sutter, 5 VIB-RUG, Gent) and was used to replace VL in pSV51E6L (De Sutter *et al.*, 1992a) by BanII-AvaI fragment exchange. The resulting vector pSVE6sFvE6CL encodes E6scFv-CL.

pSV2C11sFvE6CH1E

10 The vector pc/DNA/AMP containing the anti CD3 scFv in the VL-L-VH configuration was kindly provided by Dr. D. Segal (Bethesda, MD, USA). Via site directed mutagenesis with the linker 5' CCGTCTCCTCAGAGCTCCAAAAACCC 3' a SacI site (underlined) was created immediately after 15 the scFv. In the vector pSV51-2C11sFvMG2fEtag, the BamHI-SacI flanked 2C11scFv was fused in front of the E-tagged mouse IgG2b Fc-portion. In this vector we replaced the mouse heavy chain fragment with PCR amplified CH1 domain, digested with SacI and NotI. The CH1, domain was 20 amplified from the vector pSV51E6Hf1 with the forward primer 5' CACTGCCGAGCTCCCAAAC 3' (SacI site underlined) and the reversed primer 5' TCATGTCGCGGCCGCTCTA 3' (NotI site underlined). As a result the vector pSV2C11sFvE6CH1 was coding for 2C11scFv-CH1. Finally, the CH1 domain was 25 exchanged with the E-tagged CH1 domain from the vector pCAsc2C11E6Hf (see below) by a BalI-SalI restriction digest. This resulted in the vector pSV2C11sFvE6CH1E.

pSVBlaE6CH1E

30 The pSV71 vector containing the BlaL1Hi insert (De Sutter *et al.*, 1992b) was the source of the EcoRV-SacI insert that replaced the EcoRV-SacI excised 2C11scFv from pSV2C11sFvE6CH1E. In this way pSVBlaE6CH1E was made, coding for Bla-CH1. The 14 amino acids of linker 1 35 (VNHKPSNTKVDKRV = last amino acids of mouse IgG2b CH1 and part upper hinge) and the amino acids of the SacI site (EL) are linking both subunits, adding up to a 16 amino acid linker connecting CH1 and Bla.

pCAGGSE6L

The eukaryotic expression vector pCAGGS was a gift from Dr. J. Miyazaki (University of Tokyo, Japan) (Niwa et al., 1991) and contains an ampicillin resistance gene, the strong constitutive β -actin/ β -globin hybrid promoter and part of exon 3, 3' UTR and polyA signal of the rabbit β -globin gene. pCAGGSE6L (LMBP3547-IDA97-33, unpublished and kindly provided by Dr. J. Demolder, VIB-RUG, Gent) was made by ligating the XbaI fragment (filled-in with Klenow DNA polymerase) from pSV51E6L containing the E6L-sequence to a MscI-opened vector fragment of pCAGGS.

pCA2C11sFvE6Hf

2C11scFv-Fd gene assembly was achieved in the vector pCA2C11sFvE6Hf (LMBP3715-IDA97-34) containing the following fragments (clockwise): MscI-opened vector pCAGGS (Niwa et al., 1991); SspI-BamHI fragment from pSV51 (Huylebroeck et al., 1988), 2C11scFv encoding fragment from pcDNA/AMP/2C11 (Jost et al., 1994) cut in the BamHI- and in a introduced Ecl136II-site; Fd encoding fragment from pSV23SE6Hm (Dr. W. Lammerant, RUG, Ph.D. thesis 1994) flanked by KpnI (T4 blunted) and the 2 nucleotides of the BanII-site; NotI (Klenow blunted)-BsmI (T4-blunted) fragment from pCANTAB5E (Pharmacia LKB Biotechnology, Uppsala, Sweden) encoding the E-tag; SalI (blunted)-XbaI (blunted) fragment of pSV51.

pSVE6H1sc2C11M

The Fd-H1-2C11scFv fusion gene in pSVE6H1sc2C11M was made by ligating the NdeI (Klenow blunted)-AvaI fragment of pcDNA/AMP/2C11 (Jost et al., 1994) in the ApaI (T4 blunted)-SalI vector fragment of pSV51E6H (De Sutter et al., 1992a), encoding the E6 heavy chain that was truncated after the third amino acid of the hinge region (Fd, no cysteins included). The connecting sequence (encoding the additional EPSG) between E6Fd and 2C11scFv was confirmed by DNA sequence

analysis. This anti CD3 scFv was in the VL-linker-VH configuration and carried an c-myc tag.

pCAE6H1sc2C11H

- 5 The Fd-H1-2C11scFv fusion gene in pCAE6H1sc2C11H was also made by ligating a PCR-amplified 2C11scFv-encoding fragment to the C-terminus of E6Fd. The PCR fragment encodes the the 2C11scFv in the VH-VL configuration with a (His)₆ tail and it was amplified from
- 10 pQE-bssFvB1-2C11 (De Jonge et al., 1995, kindly provided by Dr. K. Thielemans, VUB, Belgium) with the forward primer 5' GGCCCATGGAGGTCAAGCTGGTGGAGTC 3' and the reverse primer 5' ATAGGATCCTTATCCGGACCTTTTATTTCACGCTTGGTGCCAG 3' (BamHI site underlined). This PCR fragment was cut in the
- 15 BamHI site and kinated. Subsequently we cloned in the MscI-BglII opened pCAGGS vector (Niwa et al., 1991), the HindIII (blunted)-ApaI fragment of pSV23sE6Hm (Dr. W. Lammerant, RUG, Ph.D. thesis 1994), encoding the Fd fragment, and the PCR fragment, encoding 2C11scFv.

20

pCAE6H2sc2C11H

- Fd-H2-2C11scFv gene assembly was achieved in the vector pCAE6H2sc2C11H (LMBP3716-IDA97-35), containing the following fragments: MscI-BstXI opened pCAGGS vector
- 25 (Niwa et al., 1991); HindIII(blunted)-ApaI fragment of pSV23sE6Hm (Dr. W. Lammerant, RUG, Ph.D. thesis 1994) encoding the Fd fragment; PCR fragment amplified from pQE-bssFvB1-2C11 (De Jonge et al., 1995) with the forward primer 5' GCTGAAAGGGCCCGGTGGAGG 3' (ApaI site,
- 30 underlined) and with the reverse primer 5' GGTCCAGGGCACTGGCCTCACTCTAGAG 3' (BstXI site, underlined). This PCR fragment encodes a (G₄S)₃.linker, a anti murine CD3ε scFv in the VH-VL configuration and a (His)₆-tail.

35

pCAE6L2sc2C11

The E6L-L2-2C11scFv gene assembly was performed in the vector pCAE6L2sc2C11, containing the following

- fragments: HpaI-BstXI opened pCAGGSE6L vector; PCR fragment (coding for CL) amplified from pCAGGSE6L with the forward primer: 5' CAGTGAGCAGTTAACATCTGG 3' (HpaI site, underlined) and with the reversed primer: 5' CCTTTGGGGCCCACTCATTC 3' (ApaI site, underlined);
- 5 fragment amplified from pQE-bssFvB1-2C11 (De Jonge et al., 1995) with the forward primer: 5' GCTGAAAGGGCCCGGTGGAGG 3' (ApaI site, underlined) and with the reversed primer:
- 10 5' GTGCCAGGGCACTGGTTAAGATCTGGATCC 3' (BstXI site, underlined). This PCR fragment encodes a (G₄S)₃-linker, a anti murine CD3 ϵ scFv in the VH-linker-VL configuration and a stop codon.
- 15 pCAB1E6H2sc2C11H
- The chimeric Fd chain with variable sequences derived from the anti BCL1 mAb B1 and the constant sequence derived from the anti hPLAP mAb E6: VH(B1)-CH1(E6) coupled to the anti murine CD3 2C11scFv was
- 20 assembled in the pCAB1E6H2sc2C11H vector as follows: the B1VH domain, together with its natural signal sequence, was PCR amplified from the vector pEFBOS-bssFvB1-2C11 (kindly provided by Dr. K. Thielemans, VUB, Belgium) with the forward primer 5' CCTCACCTCGAGTGATCAGCACTG 3' (XhoI
- 25 site underlined) and the reverse primer 5' CCACCTGAGGAGACAGTGACC 3' (Bsu36I site underlined). Subsequently the E6CH1 in pCAE6H2sc2C11H was flanked with a Bsu36I site by PCR amplification using the forward primer 5' CTGCTCCTCAGGCAAACAACACCC 3' (Bsu36I site
- 30 underlined), the reverse primer 5' GGACCCAGTGCATGCCATAGCC 3' (SphI site underlined). These two PCR fragment were ligated in the XhoI-SphI opened vector pCAE6H2sc2C11H.
- pCAB1E6L
- 35 The VL(B1)-CL(E6) chimeric light chain was assembled by substituting the DNA sequence of the mature VL(E6) gene in pCAGGSE6L with that of the mature VL(B1). The resulting vector pCAB1E6L contains the following

fragments (clockwise): XbaI-Tsp45I fragment of pCAGGSE6L encoding the E6H signal sequence; the VL(B1) sequence amplified from pEFBOS-bssFvB1-2C11 with the forward primer 5' GGATGTGACATTGTGATGACC 3' (Tsp45I site underlined) and the reverse primer 5' GATCCTTTGAGCTCCAGC 3' (SacI site underlined), the CL(E6) sequence amplified from pCAGGSE6L with the forward primer 5' GTTGGAGCTCAAACGGGCTG 3' (SacI site underlined) and the reverse primer 5' GGAGCTGGTGGTGGCGTCTCAGGACC 3' (BsmBI site underlined); XbaI-BsmBI opened vector pCAGGSE6L.

pCDE6L4scB1 and pCDE6L4E6

The construction strategy of this plasmid involves the construction of pCAGGSE6Lm2. This construct was made by PCR amplification of the E6L gene from pCAGGSE6L (Dr. J. Demolder, VIB-RUG) with the forward primer 5' ATACCGCTCTCGAGACACAGACATGAGTGTGCCCACTC 3' (XhoI site underlined) and the reverse primer 5' CGCGGATCCTTACCCGGGGACGTCACACTCATTCTGTGAAGCTCTTGAC 3' (BamHI site underlined) with the purpose to create additional cloning sites at the N- and C- terminus of the E6L gene.

For the construction of pCDE6L4scB1, the B1scFv was PCR amplified from the vector pFE12-B1 (kindly provided by Dr. K. Thielemans) with the forward primer 5' TCCCCCGGGGAAGTGAAGCTGGTGGAGTCTG 3' (SmaI site underlined) and the reverse primer: 5' ATAGGATCCTTATCCGGATTTCAGCTCCAGCTGGTCCCAGC 3' (BamHI site underlined). This PCR fragment was digested with BamHI and phosphorylated. Subsequently the PCR fragment was ligated with the SmaI-BsaI vector fragment of pCAGGS and the BsaI-BamHI fragment of pCDNA3.1zeo⁻ (Invitrogen). In this way a hybrid vector frame was created, designated as pCD, who's promotor region is derived from the pCAGGS vector and who's 3' untranslated region, zeocin resistance gene and multi-cloning site are derived from the vector pCDNA3.1zeo⁻.

pCDE6L4scE6 was constructed in exactly the same way, only the E6scFv gene was amplified from pSV51E6sFv (S. Dincq, VIB-RUG) with the forward primer: 5' TCCCCCGGGCAGGTTCAGCTGCAGCAGTCTGGAG 3' and the reverse 5 primer 5' ATAGGATCCCTTATCCGGACCGTTTATTTCAGCTTGGTCC 3'.

pCDE6L5scB1 and pCDE6L5scE6

These two constructs are immediately derived from the pCDE6L4scB1 and pCDE6L4scE6 vectors by inserting two complementary adaptor oligonucleotides in the AatI and XmaI sites between the E6L and the scFv genes. The oligonucleotides 5' CGACGGTGGTTCTAGAGGTGATGGGC 3' and 5' CCGGGCCCATCACCTCTAGAACCACCGTCGACGT 3' were allowed to hybridize, resulting in AatI and XmaI sticky ends and the adaptor was then cloned.

pCDE6L6scE6

This vector contains the following fragments (clockwise): XhoI-Bsp120I(blunted) fragment of pCAE6L2sc2C11 encoding E6L, AatII(blunt)-XhoI vector fragment of pCDE6L4scE6 encoding E6scFv.

pCDE6H6scE6

This vector contains the following fragments (clockwise): XhoI-Bsp120I (blunted) fragment of pCAE6H2sc2C11H encoding E6Fd, AatII(blunt)-XhoI fragment of pCDE6L4scE6 encoding E6scFv.

pCDE6L7scE6

This vector contains the following fragments (clockwise): XhoI-Bsp120I(blunted) fragment of pCAE6L2sc2C11 encoding E6L, two complementary oligonucleotides: 5' GGCTCAACCACAACCTCAGCCGCAACCTCAACCTGGGC 3' and 5' CCGGGCCAGGTTGAGGTTGCGGCTGAGGTTGTGGTTGA 3' that form Bsp120I and XmaI sticky ends, XmaI-XhoI vector fragment of pCAE6L6scE6.

pCDE6H7scE6

This vector contains the following fragments (clockwise): XhoI-Bsp120I fragment of pCDE6H6scE6 encoding E6Fd, two complementary oligonucleotides
 5' GGCCTCAACCAACCTCAGCCGCAACCTCAACCTGGGC 3' and
 5' CCGGGCCCAAGGTTGAGGTTCGGCTGAGGTTGTGGTTGA 3' that form Bsp120I and XmaI sticky ends, XmaI-XhoI vector fragment of pCDE6L6scE6.

10 Constructs with 3D5scFv

The plasmid pAK100His2 (Knappick *et al.*, 1994), coding for the anti His scFv 3D5, was a kind gift of Dr. A. Plückthun (Zurich, Switzerland). The 3D5 scFv was amplified from pAK100His2 with the forward primer 5'

- 15 TCCCCCGGGGACATTTTGATGACCCAACTCCAC 3' (SmaI site underlined) and the reverse primer
 5' ATAGGATCCTTATCCGGATTCGCCCCCGAGCCGCAGAGACAG 3' (BspEI site underlined) and was fused to an E-tag coding sequence
- 20 (TCCGGAGCGCGGTGCGGTATCCAGATCCGCTGGAACACGTGGCGCCTAAGGATC C, BspEI site and BamHI site underlined) in the pCD vector. The SmaI-SpeI fragment of this construct, encoding the E-tagged scFv 3D5 (abbreviated 3D5E), was used to assemble the following vectors:
- 25 pCDE6L4sc3D5E: Fragment 3D5E ligated to SpeI-SmaI fragment of pCDE6L4scB1
pCDE6L5sc3D5E: Fragment 3D5E ligated to SpeI-SmaI fragment of pCDE6L5scB1
pCDE6L6sc3D5E: Fragment 3D5E ligated to SpeI-SmaI fragment of pCDE6L6scE6
- 30 pCDE6L7sc3D5E: Fragment 3D5E ligated to SpeI-SmaI fragment of pCDE6L7scE6
pCAE6L8sc3D5E: Fragment 3D5E ligated to SpeI-SmaI fragment of pCAE6Lm2
- 35 pCDE6L6lmIL2

The E6L-mIL2 fusion gene was assembled by ligating the following fragments: XhoI-Bsp120I (blunt)

fragment of pCDE6L6scE6 encoding E6L, NdeI(blunt)-BamHI fragment of pLT10mIL2ST (Mertens *et al.*, 1995) encoding mIL2, and the XhoI-BamHI vector fragment of pCDE6L4sc3D5E.

5

pCDE6H61mIL2 and pCDE6H62mIL2

These vectors were assembled by ligating the following fragments: the XhoI-BamHI vector fragment of pCDE6L4sc3D5E, NdeI(blunt)-BamHI fragment of pLT10mIL2ST
10 encoding mIL2 and a fragment of pCDE6H6scE6 encoding E6Fd, excised with XhoI-Bsp120I(blunt) for the H61 linker or cut with XhoI-XmaI for the H62 linker.

Plasmids for electroporation of SP2/0 cells

15 In the vector pCAB1E6L a zeocin resistance gene was inserted by replacing the BglII-ScaI fragment of the pCAGGS vector with the BamHI-ScaI fragment of the pCDNA3.1zeo⁻ vector (Invitrogen, Carlsbad, CA, USA). This new plasmid was named pCDB1E6Lzeo. Analogously a
20 neomycine resistance gene was inserted in pCAB1E6H2sc2C11H by replacing the HindIII-ScaI fragment of the vector, with the HindIII-ScaI fragment of pCDNA3 (Invitrogen). This resulted in the vector pCDB1E6H2sc2C11Hneo.

25

Transfection protocols

Unless otherwise stated, all cultures were grown at 37°C with 5% CO₂ in Dulbecco minimal essential medium (DMEM, GibcoBRL life technologies, Paisly, UK)
30 supplemented with 10% FCS, 0.03% L-glutamine, 100 U/ml penicillin, 100 mg/l streptomycin and 0.4 mM sodium pyruvate.

Transfection of COS-1 cells was performed as described in De Sutter *et al.* (1992). HEK293T (DuBridge
35 *et al.*, 1987) cells were transfected by a Ca₃(PO₄)₂ method. 20h before transfection, subconfluent monolayers were trypsinized and reseeded at 2.25 x 10⁶ cells / 75 cm². 2 h before transfection 35 ml of fresh medium was added to

the cells. 14 μ g of sterile, ethanol precipitated DNA of each expression plasmid (purified on a Qiagen DNA purification column, Qiagen Inc., CA, USA) was redissolved in 1400 μ l 0.1 x TE buffer (1x TE: 10 mM Tris.HCl, 1 mM EDTA) pH 7.5, and mixed with 350 μ l 1.25 mM CaCl_2 , 125 mM Hepes-NaOH, pH 7.5. This DNA-solution was slowly added to 1 x Hepes/ 2x BS (25 mM Hepes-NaOH pH 7.5; 16 g/l NaCl; 0.74 g/l KCl; 0.50 g/l $\text{Na}_2\text{HPO}_4 \cdot 12\text{H}_2\text{O}$; 2 g/l Dextrose) while continuously shaking. After 1 minute additional shaking, the mixture was transferred to the medium covering the cells and incubated for 24 h at 37°C.

Subsequently, the mixture was removed from the cells and replaced by 35 ml DMEM supplemented with 0.03% L-glutamine, 100 U/ml penicillin, 100 mg/l streptomycin, 0.4 mM sodium pyruvate, 5 mg/l bovine insulin, 5 mg/l transferrin and 5 μ g/l selenium. Medium was harvested after 24 or 72 h. Dead cells were removed from the medium by centrifugation at 1100 rpm for 5 min and the culture supernatant was concentrated over a membrane with a cut-off value of 10 kDa (Centricon-10[®] microconcentrator or a Centriprep-10[®] concentrator membrane, Amicon Inc., Beverly, MA, USA).

In order to change the buffer, the concentrated supernatant containing the bispecific antibody (35 ml to 2.5 ml on Centrprep-10) was diluted with 12.5 ml PBS(A) (= 171.1 mM NaCl, 3.4 mM KCl, 10 mM $\text{Na}_2\text{HPO}_4 \cdot 12\text{H}_2\text{O}$, 1.8 mM KH_2PO_4) supplemented with 0.05 % bovine serum albumin (BSA) and 0.02 % azide, and concentrated again to 1.5 ml. Cells were lysed with 10% NP-40 (Nonidet P40), containing 10% aprotinin, 100 mM Tris.HCl, pH 8.0, and 10 mM EDTA.

HEK293T production of Fab-scFv BsAb

For HEK293T production of 1 mg bispecific B1Fab-scFv we seeded 4×10^7 HEK293T cells in 10 cultureflasks of 175 cm² and after 24 hours these cells were cotransfected with pCAB1E6L and pCAB1E6H2sc2C11H (140 μ g of each plasmid) using the standard $\text{Ca}_3(\text{PO}_4)_2$ transfection method described. After 24 h the precipitate

was removed and the cells were allowed to grow in ITS supplemented medium. Every 48h, this medium was harvested and changed. This was repeated six times resulting in 1.75l medium that was filtered with a bottle top filter (Nalgene).

Electroporation of Fab-scFv in SP2/0 cells

SP2/0-Ag14 cells, growing in log phase were harvested and resuspended at 4×10^6 cells in 400 μ l growing medium (RPMI 1640, supplemented with 10% foetal calf serum, 0.03% L-glutamine, 100 U/ml penicillin, 100 mg/l streptomycin, 5×10^{-5} β ME and 0.4 mM sodium pyruvate) and kept on ice. 15 μ g of each plasmid (pCDB1E6Lzeo and pCDB1E6H2sc2C11Hneo) was linearized by a ScaI digest. The plasmids were ligated and the mixture was purified by a phenol-ether extraction, precipitated and resuspended in 20 μ l bidest. 1 minute before electroporation the DNA was mixed with 4×10^6 cells in the electroporation cuvet (gap 0.4 cm) and kept on ice. The electric pulse (900 μ F, 250 V) was generated by an EASYJECT Plus (Molecular Technologies inc., St Louis, MO, USA). Immediately after the pulse 1 ml of fresh medium was added to the cells and they were transferred to a 12 cm² culture plate. 48 h later the electroporated cells were incubated with growing medium containing 0.6 mg/ml zeocin) and 0.6 mg/ml neomycin. After 30 days the surviving cells were transferred to larger culture flasks or diluted for subcloning, and the culture medium was analysed.

30

Characterization of expressed proteins

Concentrated medium fractions of transfected cells corresponding to 500 μ l supernatant, were diluted with 3 x non-reducing sample buffer (New England Biolabs, Beverly, MA, USA), boiled for 5 min and subjected to 10 % SDS-PAGE (Laemmli, 1970). After gel electrophoresis, the proteins were transferred to a nitrocellulose membrane (BA85; 0.45 μ m; Schleicher & Schuell, Dassel, Germany)

Subsequent detection of the proteins on the blot was performed as follows: after blocking the membrane in blocking solution (5% (w/v) reconstituted, dried skimmed milk in 50 mM Tris.HCl, pH 8.0, 80 mM NaCl, 3 mM NaN_3 , and 0.2% NP-40), the blots were incubated for 1.5 h with the anti murine γ and κ detection sera each 1:1000 diluted in blocking solution (goat anti murine Ig serum and goat anti murine κ serum, both 1 mg/ml, Sera-Lab LTD, Crawley Down, U.K.). Subsequently the blots were washed three times with blocking solution and incubated for another 1.5 h with rabbit anti goat IgG serum conjugated to alkaline phosphatase (Sigma Immuno Chemicals, St-Louis, MO, USA) 1:7500 diluted in blocking solution. Finally, the membrane was washed extensively with substrate buffer (0.1 M Tris.HCl, pH 9.5, 0.1 M NaCl and 50 mM MgCl_2) and then developed by incubation with nitro-blue-tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate (Promega, Leiden, The Netherlands) in substrate buffer. This staining reaction was stopped by rinsing the blot with water.

The antigen-binding capacity after blotting was analyzed by incubation of the blocked filter with soluble hPLAP (Sigma Chemical Co., St-Louis, MO, USA, final concentration 0.1 U/ml in blocking solution), followed by the specific enzymatic staining reaction as described above.

For densitometric measurements, the blots
30 containing immunoreactive signals were scanned with a
desktop scanner and analyzed by the whole Band Analyses
software (Bio Image, Ann Arbor, MI, USA). The integrated
intensity was calculated for each lane in terms of
percentage.

35 Anti E-tag immunodetection was achieved with an murine anti E-tag antibody (1:1000, Pharmacia LKB Biotechnology, Uppsala, Sweden). Anti His-tag

immunodetection was achieved with anti-His tag antibody (Qiagen Inc, Valencia, CA, USA).

Both incubation steps were followed by a anti-murine IgG1 serum conjugated to alkaline phosphatase (Pharmingen, San Diego, CA, USA). Subsequent enzymatic staining was performed as described above.

The purified and biotinylated BCL1 IgM molecule was a kind gift of Dr. K; Thielemans (VUB, Belgium). It was used in a final concentration of 1 μ g/ml to incubate immunoblots containing the B1Fab-scFv or B1scFv molecule. Subsequently the blot was treated with streptavidin conjugated to alkaline phosphatase (Life Technologies, Paisley, UK) and stained with the same enzymatic reaction as described above.

15

IMAC purification of bispecific Fab-scFv

Column preparation:

For large scale purification a Hi-Trap chelator column (Pharmacia) was used. The agarose beads of the column were thoroughly rinsed with bidest, loaded with 1 column volume of 0.1 M NiSO_4 and immediately rinsed with 5 column volumes of bidest.

Sample preparation:

The HEK293T supernatant was concentrated, dialyzed to 150 ml PBS(A), supplemented with imidazole to a final concentration of 10 mM and subsequently adjusted to pH 7,5.

Purification:

The column was equilibrated with 10 volumes of starting buffer (PBS(A) containing 50 mM imidazole, 10% glycerol, pH 8,5) and loaded with the sample using a luer lock syringe. The flow trough was collected.

Ten volumes of starting buffer were used to wash the column and the bispecific Fab-sFb was eluted with PBS(A) containing 400 mM imidazole, pH 8.5.

Concentration, dialysis and functional analysis of the purified B1Fab-scFv

The eluted fractions were concentrated by ultrafiltration (Centricon system, Amicon), diluted in 5 PBS(A) and concentrated again to a final volume of 300 μ l. Protein concentration was measured with a Biorad DC protein assay (Bio-Rad Laboratories, Hercules, CA, USA) and was determined to be 4 mg/ml. The final amount of purified B1Fab-scFv was 1.3 mg. The purified B1Fab-scFv 10 was used in a T-cell proliferation assay as further described and found to be functional. 1 μ g of purified BsAb gave rise to a proliferative response comparable as with 1 μ g non-purified protein (data not shown).

15 Flow cytometry

TE2, CD3⁺ Th-1 cells (Grooten et al., 1989), mouse fibrosarcoma MO4 cells, MO4I4 cells, transfected with the hPLAP gene (Hendrix et al., 1991; kindly provided by Dr. M. De Broe, University of Antwerp, 20 Belgium) and BCL1^{vivo} cells (obtained from Dr. K. Thielemans) were used for flow cytometric experiments.

Purified murine monoclonal anti hPLAP antibody E6 (De Waele et al., 1988; Flamez et al., 1995), was used to verify hPLAP expression on the MO4I4 cells. A purified 25 fraction of the parental anti murine CD3 ϵ 145-2C11 monoclonal antibody (Leo et al., 1987, kindly provided by Prof. Dr. J. Plum, RUG, Gent), was used to verify the CD3-expression on TE2 cells (data not shown). For indirect immunofluorescence staining, TE2 cells (CD3⁺) 30 were washed with RPMI1640 medium and resuspended (25 x 10⁴ cells per sample) in 500 μ l of the concentrated and dialysed, BsAb (ahPLAP x α CD3) (4 μ g) and subsequently incubated on ice for 60 min. Likewise, MO4I4 (hPLAP⁺) cells were washed with RPMI medium and 25 x 10⁴ cells were 35 incubated with the BsAb (ahPLAP x α CD3). After three wash steps with incubation buffer (PBS(A) supplemented with 0.5% BSA and 0.02% NaN₃), the cells loaded with BsAb were incubated for 60 min on ice in a 1:1000 dilution of

004270-005260

fluorescein-conjugated goat (Fab')₂ fragment to mouse IgG (Fab')₂ (Cappel, West Chester, UK). After a final wash procedure, all cells were resuspended in 300 µl incubation buffer and immediately analysed by flow cytometry, (FACSCalibur; Becton Dickinson, Sunnyvale, CA).

Green fluorescence intensity was measured for the living cell population, which was constantly kept at 4°C. Presentations of the resulting histograms were processed with the WinMDI-software (multiple document interface and Flow cytometry applications, version 2.1.3, TSRI, <http://facs.scripps.edu/software.html>).

Flow cytometric analysis of the bispecific character of BsAb (αBCL1 x αCD3) was essentially performed in a similar procedure, but here different tumor cells and detection systems were used. For immunofluorescence staining of the TE2 (CD3⁺) cells pre-treated with BsAb (αBCL1 x αCD3) (15 µg/ml) we used the biotinylated BCL1 IgM antibody (gift Dr. K. Thielemans) followed by FITC-conjugated streptavidin (Sera-Lab LTD, Crawley Down, U.K.). BCL1^{vitro} cells (BCL1⁺) were used to analyse the binding capacity of the chimeric Fab subunit of the bispecific antibody. The cells were loaded with BsAb (αBCL1 x αCD3) and subsequently stained with the following detection antibodies: anti-His tag antibody (Qiagen Inc, Valencia, CA, USA), anti mouse IgG1 (Sigma), anti goat FITC conjugated (Sigma). Finally the green fluorescent cells were counted with a FACSCaliber cytometer.

Flow cytometric analysis of the trispecific (αhPLAP x αBCL1 x αCD3) and the Fab-(scFv)₂ molecule was essentially performed as described above, but different detection antibodies were used: anti mouse IgG γ/κ (1:200 dilution) and chicken anti goat IgG (H+L) FITC (1:200 dilution, Chemicon, Tenecula, CA, USA).

T-cell proliferation assay

For the hPLAP tumor model we used MO4I4 tumor cells and splenic T-cells from syngenic C3H/HeOUico, for the BCL1 lymphoma cells we used T-cells from syngenic BALB/c mice. All mice were purchased from the Charles River group (Sulzfeld, Germany) and kept and treated according to guidelines issued from the local ethical commission for animal experiments.

MO4I4 and BCL1^{vitre} tumor cells were pre-treated with 50 µg/ml mitomycin C at 37°C in the dark for 12h and 1.5h respectively. After removal of the mitomycin C, 5 x 10⁶ tumor cells were co-cultured with the corresponding 1 x 10⁵ splenic T-cells in a round bottom well in the presence of the indicated concentration of the BsAb (αhPLAP x αCD3) (αBCL1 x αCD3) or the trispesific molecule (αhPLAP x αCD3 x αBCL1). After 48 h, the cells were pulsed with 0,5 µCi of tritium-thymidine ([³H]TdR 1mCi/ml, Amersham). 18 h later the cells were lysed by freezing, the DNA was harvested with an automatic cell harvester and the incorporated radioactivity was measured by scintillation counting using a Top-count machine (Packard, Meriden, CO, USA)

⁵¹Cr release assay

Primary alloreactive CTL responses were generated and investigated with a standard ⁵¹Cr release assay. Briefly, 4 x 10⁶ splenic syngenic responder cells (C3H/HeOUico for the hPLAP tumormodel, BALB/c for the BCL1 tumor model) were mixed with 4 x 10⁶ splenic allogenic stimulator cells (C57Bl/6) that were treated with 50 µg/ml mitomycin C for 60 min at 37°C in the dark. The mixed cell population was cocultured in 2 ml cultures in complete medium (RPMI 1640, with 10% foetal calf serum, 0.03% L-glutamine, 100 U/ml penicillin, 100 mg/l streptomycin, 0.4 mM sodium pyruvate and 5 x 10⁻⁵ M βME) in the presence of 30 U/ml mIL2. These cultures were incubated at 37°C in 5-7% CO₂ in humidified air for 5 days.

Tumor cells (MO4I4 or BCL1^{vitro}) were incubated with 150 μ Ci Na⁵¹CrO₄ (Amersham, Ghent, Belgium) for 90 min at 37°C and washed carefully (to minimize the spontaneous release). Effector cells from the mixed lymphocyte culture were harvested, washed and 25 x 10⁴ cells were plated in triplicate in 96 well U-bottom plates (Falcon, Becton Dickinson, Mountain View, CA, USA) containing 5 x 10³ tumor cells and bispecific antibody (1 μ g/ml). The effector/target ratio is 50/1 in a total volume of 200 μ l. After 4 h incubation at 37°C, 30 μ l of the culture supernatant was transferred to a luma-plate (Packard, Meriden, CO, USA), air dried and measured with a Top-count machine. The percentage of specific lysis was calculated as 100 x [(experimental release)-(spontaneous release)/(maximum release)-(spontaneous release)]. Maximum release was the value obtained from target cells incubated with 2 % SDS. The spontaneous release never exceeded 14 % of the maximum release.

20 Serum stability in vitro

Serum preparation and sample incubation:

Balb/c mice were treated with an anaesthetic (3.75 mg avertin) and their blood was taken by cardiac puncture. The blood was incubated at 37°C for 60 min, then stored at 4°C for 60 min and subsequently centrifuged at 14 000 rpm for 10 min. The serum was filter sterilised and the Fab-scFv sample was added to a final concentration of 4 μ g/ml. This was divided in three batches (each 150 μ l) and incubated at 37°C in sterile conditions. After several periods of time (2 h, 12 h and 24 h), one of the batches was frozen until further analysis.

35 Analysis of the remaining activity of Fab-scFv BsAb after serum incubation

The serum stability of the novel Fab-scFv BsAb was investigated using a standard T-cell proliferation assay. We argued that the remaining functional activity

in the serum-incubated samples is correlated to the serum stability of the bispecific protein. The frozen serum samples were submitted in triplicate to a T-cell proliferation assay as described earlier.

5

EXAMPLE 1**Heterodimerization by CL-CH1 interaction in eukaryotic cells can depend on appropriate VL-VH pairing**

In a first attempt, minibodies were constructed using the CL and CH1 domain on their own to promote heterodimerization of two different scFv molecules. However, after cotransfection of expression plasmids for the VH-VL-CL (scFv-CL) and the VL2-VH2-CH1 (scFv-CH2) fusion proteins, largely all secreted immunoglobulins, detected by an anti mouse IgG γ/κ serum were in the monomer format. Inclusion of an E-tag on the C-terminus of the CH1 domain, allowed for the easy discrimination between scFv-CL and the E-tagged scFv-CH1 by immunodetection with an anti E-tag antibody. This clearly showed that the monomers were not scFv-CH1 and that the slight amount of dimers formed did not contain the scFv-CH1 fusion molecule, and hence consisted of scFv-CL molecules alone (data not shown). To avoid possible steric hindrance caused by the fusion of the scFv molecules to the CL and CH1 domains, a derivative was made with a longer flexible linker (16 amino acids: VNHKPSNTKVDKRVEL) separating the fusion partner from CH1. For simplifying the analysis of the construct we used a β -lactamase molecule as a fusion partner, which allows for detection of heterodimers simply on the basis of molecular weight. When co-expressing the bla-CH1 fusion with the scFv-CL fusion, only CL-containing products could be found in the medium with anti mouse IgG γ/κ immunodetection. This is especially remarkable since this was also true when the bla-CH1 fusion was co-expressed with a native L chain. L-chains or L-chain derivatives can be expressed on their own and appear as monomers and as homodimers, so they can be secreted without

- association to any other partner. The bla-CH1 fusion is not expected to hinder the association of CH1-CL, so it was expected that a L:bla-CH1 dimer should be formed by the interaction of CL and CH1. No product can be seen
- 5 with the expected molecular weight of the intended heterodimer (Figure 2A). Furthermore, immunodetection with the highly sensitive anti E-tag antibody failed to reveal any trace of a L:bla-CH1 heterodimer (data not shown).
- 10 However, in the reversed situation when a scFv-CL fusion was co-expressed with a native Fd chain (VH1-CH1), a scFv-CL:scFd heterodimer could be formed (Figure 2B, molecule A3), even when the Fd chain was N-terminally extended with another scFv (scFv-CL:scFv-Fd) (Figure 2B,
- 15 molecule C1). A more efficient heterodimerization however was observed when the scFv-Fd fusion was co-expressed with the native L chain. This resulted in a bispecific antibody by genetic fusion of a scFv fragment to the N-terminus of the Fd chain of a Fab fragment (Fig 2B,
- 20 molecule C2), which is a novel format for bispecific antibodies. Due to the fact that the hinge region is not included, both binding specificities remain monovalent.
- Both VL-CL:VL-CL (L:L) and VH-CH1:VH-CH1 (Fd:Fd) homodimers could theoretically be formed.
- 25 Especially L-chain dimer has already been described. The Fd-chain dimer has never been observed, as is also shown in Figure 2C: the complete Fab fragment and L-chain dimer can be expressed, while Fd expression is not detectable in the medium nor in the cellular fraction. This can
- 30 possibly be due to the described association of endoplasmic chaperones such as BiP with an unpaired Fd chain. When association of the L chain is postponed, the Fd-chain could be degraded instead.
- BiP is an endoplasmic (retained in the ER by a KDEL-
- 35 sequence) chaperone of the HSP70-family that generally binds to exposed hydrophobic patches. The association of BiP with Fd chains or to CH1 domains alone could be responsible for the failure of all scFv-CH1 or BLA-CH1

09525709-072400

fusion molecules to pair with an L-chain or a scFv-CL fusion protein. In these molecules, the CH1 domain is not preceded by a VH domain that then could pair with an appropriate VL domain. This could be explained if BiP binds mainly to the CH1 domain, and the displacement could only occur efficiently when also the VH-VL interaction also contributes to the binding energy. If the interaction energies of CH1 with BiP or with CL are at least in the same range, displacement of the chaperone would be inefficient unless the additional free energy of binding, contributed by the interaction of VH with VL, favors displacement. Prolonged unproductive association of BiP with CH1 containing fusion molecules could then lead to targeting the molecules for degradation.

Figure 2 shows that the heterodimerization of CL- and CH1 containing molecules in eukaryotic cells can be dependent on the pairing of appropriate VL and VH domains. The expected molecules after co-expression of CL- and CH1 containing fusion proteins are schematized. Light chain derived domains are in black, heavy chain derived domains are in white, 2CL derived domains are hatched. A Western blot, developed with anti mouse IgG γ/k serum, of a 10% non-reducing SDS-PAGE loaded with supernatant fractions from COS-1 cells, is shown. Beside the pictures of the gels the position of the molecular weight markers (kDa) is shown, as well as the configuration and position of the molecules seen on the gel.

In the figure filled symbols represent all domains from CL-containing molecules; open symbols represent domains from CH1-containing molecules.

A) Co-expression of 2cllscFv-CH1 with E6scFv-CL (molecule A1) or with the natural E6L chain (molecule A2), and of a bla-CH1 fusion (separated by an elongated linker sequence) with E6scFv-CL (molecule B1) or with the natural E6L chain (molecule B2). In lane L1 the E6scFv-CL and in lane L2 the E6L chain alone are loaded. Otherwise, the expected molecule is shown on top of each lane. In

Bj Lane L1 shows expression of E6scFv-CL alone. Co-expression of E6scFv-CL with an N-terminally extended Fd chain (C1) in stead of an N-terminally extended CH1 molecule (cfr A1 and B1) did result in the formation of an expected heterodimer, although the efficiency of heterodimerization is low. The heterodimerization efficiency was increased up to more than 90% by co-expressing the scFv-Fd fusion with the natural L chain (C2).

20 EXAMPLE 2

One of the disadvantages of using smaller recombinant BsAb molecules such as (scFv)₂ molecules or dimerized scFv molecules is the relative short reach to far apart antigens. This is especially important if the molecules are intended to link two different cells. When the Fab chains are used as a heterodimerization motif, they can constitute a binding specificity on their own. To improve upon the interaction range, the second specificity was fused to the other side (C-terminus) of the location of the binding specificity of the Fab fragment. Since a scFv molecule confers the second binding specificity, the molecular weight will still be low enough to allow rapid tissue penetration, while being high enough to avoid rapid body clearance.

The artificial peptide linker used to connect the scFv to the Fd or the L chain should not contain a

functional hinge region, since this motif can be responsible for a homodimerization of two BsAbs, making them bivalent for each binding specificity. This can be a disadvantage for some applications, since some receptors can be triggered by crosslinking, leading to premature activation or inactivation of the effector cell. Monovalent binding specificities are for example of great importance when using the molecule to retarget T cells to a tumor site. A bivalent anti-CD3 binding could lead to systemic CD3 cross-linking, leading to a temporarily T cell activation and a sustained T cell anergy. Also, for some membrane markers, a bivalent binding might induce internalization and removal of the molecule from the cell surface. It is thus important to use the Fab fragment as a dimerizing unit and not the Fab'. If a functional hinge region is included, it will act as a homodimerization motif on its own, doubling the binding specificities in a substantial part of the expressed molecules, even if two different molecules are expressed together.

We have explored the possibility to create monovalent BsAb molecules by fusing a scFv molecule via a linker to the C-terminus of either the Fd or the L chain (Figure 3A). Using this as a model system for the creation of BsAb we were able to obtain very specific heterodimerization of the L with the Fd-scFv molecules. Up to more than 90% of the secreted immunoglobulin proteins was in the desired bispecific format (Fig. 3A). Furthermore, the L:Fd-scFv format allows efficient production of the BsAb from the culture medium of the transfected cells. Without amplification, up to 10 μ g BsAb/ml culture medium could be obtained.

Apparently, the length and composition of the peptide linker connecting the L and the scFv molecules can be varied without any significant drop in the expression of the L-scFv:Fd heterodimer (Figure 3B). The Fab-scFv fusion protein was expressed as the major immunoglobulin derived product as is shown by immunodetection with anti IgG γ/κ and anti E-tag

00225043-072400

antibodies. Revelation of the blotted proteins with hPLAP showed the functionality of the Fab fragment. A longer linker could allow a further range of reach for antigen, while a shorter linker, or a different amino acid

5 sequence, might stabilize the fusion product. This could be important when the flexible linker should be vulnerable for proteases present in the environment where the BsAb is expected to function.

As a model for a monovalent BsAb we further
10 characterized the (α hPLAP)Fab-(α CD3)scFv with the (G4S)₃ peptide linker (H2) for functional binding to cells expressing hPLAP (M₄OI₄ fibrosarcoma cells) or CD3 (TE2 T cells) on their membrane. The Fab-scFv BsAb (α hPLAP x α CD3) was shown to efficiently bind both cells, proving
15 the functionality of both binding sides of this new model for BsAbs (Figure 4A). This binding was not observed with cells that did not express the hPLAP or the CD3 markers (data not shown). To exclude the possibility that fractions of the BsAb bind only one antigen at the same
20 time, we assayed the functionality of the BsAb to bind two cells at the same time. This was done using a T-cell proliferation assay and a T-cell cytotoxicity assay (Figure 4B). These assays clearly showed that indeed the BsAb could bind two different cells at the same time. A
25 clear dose dependent T cell reaction could be seen only when the BsAb with the appropriate specificities (α hPLAP x α CD3), and hPLAP expressing cells were used. This clearly proves that the new Fab-scFv model is functional as a bispecific antibody derivative and can redirect CTL
30 activity towards tumor cells.

The Fab part of the molecule can also be a hybrid molecule, where the different domains are derived from different antibodies. Such a chimeric Fab can be constituted from a VH and a VL with a defined
35 specificity, fused to constant domains derived from a different antibody. In figure 5A the expression of a BsAb containing a hybrid Fab fragment with VH and VL domains derived from the B1 anti-BCL1 antibody and constant

000225349-072400

domains from the E6 anti-hPLAP antibody is shown to be successfully produced. Again the heterodimerization of the desired bispecific molecule was very selective. The functionality of the binding specificities was shown by 5 flow cytometry and by functionality in a T-cell proliferation assay and an antibody directed T-cell lysis assay (Figure 5B).

Fusing a second functionality to the Fd chain has the additional advantage that affinity purification 10 targeted towards the Fd-scFv fusion (e.g. by inclusion of a His-tag in the molecule) removes the remaining non-functional L-chains. As mentioned, Fd:Fd homodimers never occur, so every Fd-chain or Fd-containing fusion protein is paired only with an L-chain or an L-chain derivative 15 and are therefore in the bispecific format. Due to the efficient heterodimerization of the Fd and the L chain, the main heterologous product formed by transient or stable transformed cell lines is the desired product. Figure 6A shows that the BsAb can be efficiently 20 expressed in a transiently transformed HEK293T cell line (1µg/ml culture medium) and in a stable transformed SP2/0 defective myeloid cell line (up to 10 µg/ml culture medium). After one-step affinity purification a 70-90% pure BsAb preparation could be obtained, depending 25 whether the medium contained FCS or not. The purified BsAb was still active in a T-cell proliferation assay (data not shown). Incubation for up to 24h in fresh serum derived from mouse did not result in a significant loss in activity (<30%), again measured by a T-cell 30 proliferation assay (Figure 6B).

Figure 3 shows the expression of C-terminal Fab-scFv fusion proteins. The model of the BsAb intended by co-expression of two chains is schematically 35 represented. Filled rectangles represent light chain derived domains, open rectangles heavy chain derived domains. 145-2C11 derived domains are hatched The BsAbs were created by fusing the E6 (αhPLAP) Fab fragment to either the 2c11 (αCD3) or the 3D5 (αHIS) scFv molecules.

004225045-072400

Different linker sequences were used to fuse the scFv to the C-terminus of either the L-chain (L2, 4, 5, 6, 7 and 8) or the Fd-chain (H1 and 2), ranging from 4 to 20 amino acids long. The amino acid composition is depicted with a single letter code. The pictures are from protein blots after non-reducing 10% SDS-PAGE of HEK 293T supernatant (harvested 24 h after transfection). The position of molecular weight markers is indicated beside the gel (M).

A) Co-transformation of the L and Fd-scFv expressing vectors result in a high degree of L:L homodimers and relative few Fab-scFv heterodimer (D1). Reversal of the orientation of the scFv (VHVL instead of VLVH) however resulted in more than 90% specific heterodimerization, with few contaminants of unpaired or homodimerized L-chains (D2), while keeping the connecting linker sequence. Essentially the same results were obtained when the interconnecting linker sequence was enlarged to 20 amino acids (D3), or when the scFv was fused to the C-terminus of the L-chain. The blots were probed with goat anti-mouse IgG γ/κ serum and revealed with an anti goat alkaline-phosphatase conjugated serum and NBT/BCIP.

B) Expression of a BsAb formed by coupling an anti-His scFv, also in a VLVH format, to the E6 L-chain molecule using five different linker sequences. Immunodetection of the blotted proteins by anti mouse IgG γ/κ and anti E-tag shows that all detectable immunoglobulin molecules are in the expected heterodimer format. The first blot was revealed with hPLAP, showing the functionality of the E6 Fab part of the molecule.

In figure 4 it is shown that the C-terminal Fab-scFv fusion proteins are functional as bispecific antibodies.

A) Functional cell binding of the Fab-H2-scFv (α hPLAP x α CD3) BsAb was demonstrated by flow cytometry on hPLAP-expressing fibrosarcoma cells (MO4I4) and on CD3 expressing T cells (TE2). The cells were incubated with the secondary detection antibody anti-mouse (Fab')₂-FITC

(open curves) or pre-treated with the bispecific E6Fab-scFv and subsequently incubated with the detection antibody (filled curves). The bispecific Fab-scFv showed binding both to CD3⁺ cells and to hPLAP⁺ cells with
5 satisfactory affinity.

B] Functional cell-cell ligation through the Fab-scFv was demonstrated by T-cell activation upon cross-linking of CD3. The first assay measures T-cell proliferation as a response to the bridging of tumor cells
10 and spleen cells mediated by the Fab-scFv BsAb (α hPLAP x α CD3) protein. For the hPLAP tumor model mitomycin treated M04I4 cells were cocultured with C3H spleen cells (target/responder ratio: 1/20). The non-hPLAP binding Fab-scFv BsAb (α BCL1 x α CD3) protein was used as a
15 control. T-cell proliferation was measured by tritium incorporation and depends on the concentration of the bispecific Fab-scFv.

The second assay measures the killing of the M04I4 target cells by BsAb retargeted cytotoxic T-cells.
20 A diagram is shown of the cytotoxic response of alloreactive, syngeneic C3H spleen cells upon incubation with ⁵¹Cr labelled M04I4 cells and in the presence of the proper bispecific Fab-scFv. The Fab-scFv BsAb (α hPLAP x α CD3) was able to bridge the effector cells to the target
25 cells (cell ratio 50/1) while the control Fab-scFv (α BCL1 x α CD3) BsAb was not. Specific lysis was calculated by dividing the measured lysis minus the spontaneous lysis by the difference between the maximum lysis and the spontaneous lysis. Non-specific lysis was
30 not over 10% of the maximal lysis.

In both assays, a specific T-cell activation could be noticed that was dependent on the presence of the hPLAP tumor antigen (data not shown), and on the presence and concentration of the Fab-scFv (α hPLAP x
35 α CD3) BsAb.

Figure 5 demonstrates that chimeric Fab molecules can be used to construct Fab-scFv bispecific antibodies.

0965343-072400

A] Schematic representation of a Fab-scFv BsAb molecule containing chimeric Fab chains. In this example, the VH1 and VL1 domains are derived from the moAb B1, with an anti-BCL1 lymphoma specificity. The hybrid fusion molecule could efficiently be expressed in HEK293T cells as can be seen on the Western blot of a 10% non-reducing SDS-PAGE loaded with supernatant containing the molecules Fab-scFv (α BCL1 x α CD3) BsAb (lane 1) or the control molecule bssFv (De Jonge et al.; 1995). The detection system used is mentioned underneath each panel. The detected products and the molecular weight markers (kDa) are indicated.

The chimeric Fab-scFv (α BCL1 x α CD3) BsAb retained binding specificity as shown by flow cytometry. Histograms are shown of flow cytometry analysis of BCL1^{vitro} cells and TE2 CD3⁺ T-cells, incubated with the Fab-scFv (α BCL1 x α CD3) BsAb and subsequently incubated with the detection antibody (filled curves) or incubated with the detection antibodies alone (open curves). Binding on the BCL1 B-cell lymphoma cells was detected by an anti HIS antibody (Qiagen, DE), followed by incubation with a goat anti mouse IgG1 serum and with a FITC-coupled anti goat serum. Binding to TE2 T-cells was demonstrated by incubation with the biotinylated ideotypic BCL1 IgM moAb followed by incubation with FITC-coupled streptavidin. The Fab-scFv (α BCL1 x α CD3) BsAb showed binding to both CD3⁺ cells and BCL1⁺ cells with satisfactory affinity.

B] The chimeric Fab-scFv (α BCL1 x α CD3) BsAb was proven to be active as a BsAb by antibody and target cell dependent activation of T cells, measured by proliferation and specific cytotoxicity assays. The curves show T-cell proliferation as a response to the bridging of lymphoma cells and spleen cells mediated by the Fab-scFv (α BCL1 x α CD3) BsAb protein. Mitomycin treated BCL1 cells were cocultured with Balb/c spleen cells in a target/responder ratio of 1/2. T-cell proliferation was measured by tritium incorporation and

004220-49022860

decreases with the dilution of the bispecific Fab-scFv. The diagram shows the cytotoxic respons of alloreactive, syngeneic Balb/c spleen cells upon incubation with ^{51}Cr labelled BCL1^{vitr} cells in the presence of the proper bispecific Fab-scFv. The $\alpha\text{BCL1} \times \alpha\text{CD3}$ Fab-scFv is able to bridge the effector cells to the target cells (effector/target ratio 50/1) while the control BsAb with identical structure but a different specificity ($\alpha\text{hPLAP} \times \alpha\text{CD3}$) was not.

- 10 Figure 6 illustrates the expression, purification and serumstability of bispecific Fab-scFv molecules ($\alpha\text{BCL1} \times \alpha\text{CD3}$).

A) Immobilized metal affinity chromatography of bispecific Fab-scFv BsAb ($\alpha\text{BCL1} \times \alpha\text{CD3}$). The culture medium of transiently (HEK293T) or stable (SP2/0) transfected cells was loaded on a NTA-Ni²⁺ chelating column, eluted with imidazol and analyzed on a non-reducing 10% SDS-PAGE gel and stained with Coomassie Brilliant Blue (CBB). The purified Fab-scFv fractions were loaded in high amounts (10 and 50 μg) to enable the detection of small contaminating bands. For reference, standard plasma globulin (Sigma) was also loaded in the same quantities. The position of the Fab-scFv BsAb and its molecular weight is indicated. Molecular weight markers (kDa) are indicated on the side of the gel.

B) Serum stability of a Fab-scFv ($\alpha\text{BCL1} \times \alpha\text{CD3}$). Purified BsAb fractions were incubated for up to 24h in freshly isolated mouse serum. After incubation, the fractions were compared for their biological activity in a T-cell proliferation assay. Balb/c spleen cells were co-cultivated with mitomycin treated BCL1^{vitr} cells in the presence of the bispecific B1Fab-scFv incubated in serum for 2, for 12 h or 24 h. Serum without bispecific B1Fab-scFv gave no response. There was no significant loss in activity of the bispecific Fab-scFv after 24 h of serum incubation.

EXAMPLE 3**Fd:L mediated heterodimerization of two different scFv molecules: efficient expression of trispecific antibodies**

Since C-terminal scFv fusion to either the Fd or the L chain could be expressed successfully and resulted in functional molecules, we investigated whether the Fab molecule could still be formed if both chains were elongated. When using the L:Fd heterodimerization signal to join two scFv molecules, a trispecific molecule can be created by also using the specificity of the Fab molecule created by the L:Fd heterodimerization. This was done by co-transfecting a VL-CL-VH2-VL2 (L-scFv) with a VH-CH1-VH3-VL3 (Fd-scFv) fusion-protein expressing vector (Figure 7A). Especially when fusing two scFv molecules at the same side of the molecule it is important to monitor if binding functionality is not affected by the configuration of the TsAb. Fv domains have their antigen recognition side more oriented towards the N-terminal side, while this is also the side where the fusion to the Fab chains occur. Since the scFv molecules can be expected to direct their binding side more towards the Fab fragment, the possibility exists that by the 'crowding' by both the Fab and the second scFv, the binding to an antigen of the first scFv is hindered. From studies on linkers used in scFv molecules it is known that 15 amino acids are necessary to span the diameter of a Fv domain. Therefore we assume that such a linker would allow the scFv molecule to rotate its binding side away from the Fab. Furthermore, two single chain molecules could be hindering the normal interaction between the L:Fd pair and thus inhibit the heterodimerization of the TsAb. Therefore we constructed a series of molecules with varying peptide linkers connecting the Fab with the scFv molecules in two different TsAb models (Figure 7A and 7B). Surprisingly, even the shorter linker sequences (4 amino acids) allowed efficient heterodimerization, and did not inhibit the function of the attached scFv molecules (Figure 7 and 8). The TsAb (α hPLAP x α BCL1 x

09625049.072100

αCD3) with a six amino acid linker connecting the αBCL1 scFv with the αhPLAP Fab and with a 20 amino acid linker connecting the αCD3 scFv with the Fab was further characterized. All binding specificities separately for 5 cells expressing the appropriate marker could be demonstrated (Figure 8A), as well as the simultaneous binding of one specificity to a (solid) support, while detecting via a second functional group (Figure 8B). In order to show that the molecular design of the TsAb could 10 allow the molecules to cross-link two antigens that were each fixed on the membranes of a different cell, we measured T-cell activation with a proliferation assay. Since the TsAb contain a binding site for two different tumor markers (hPLAP and BCL1) combined with an αCD3 15 specificity, the TsAb should be able to function in a proliferation assay with hPLAP-expressing cells as well as in a proliferation assay using BCL1 expressing cells. Figure 8C shows that this is indeed the case: the TsAb (αhPLAP x αBCL1 x αCD3) combines the activity of two 20 separate BsAbs (αhPLAP x αCD3) and (αBCL1 x αCD3), showing a simultaneous activity of the molecular parts along two crucial axes. Clearly, there was no problem of intramolecular crowding that inhibited the αBCL1 scFv to bind even a lymphoma cell, while also attached to a T- 25 cell via the second scFv.

This molecule design allows free choice on the position of the binding sites and valence of the end product. A useful molecule with three functional groups could be a bispecific antibody targeting two different 30 tumor antigens instead of one (Figure 7 and 8). A bivalent binding to the target cell receptor could be useful if the receptor is only triggered by forming larger aggregates and is insensitive to mere dimerization. In this case, the bivalent binding will 35 accelerate the formation of aggregates at the target site (Figure 9A). Otherwise, molecules with bivalent or multivalent binding to the target cell while keeping a monovalent binding for the triggering receptor on the

effector cell could be useful to improve on the biodistribution of the antibody derivative (Figure 9B). To improve on binding avidity, it is possible to create multivalent binding antibody derivatives with only one 5 specificity (Figure 9C). This design could be of importance in order to improve the avidity of molecules to be used for e.g. detection and diagnostics, in vitro as well as in vivo.

The Fd and L chains can also be C-terminally 10 extended with other molecules than scFv's. The targeting of certain signaling molecules to a predetermined cell type can be useful in therapeutic and diagnostic set up. We show that it is possible to use the L:Fd heterodimerization to associate two IL2 molecules, one 15 fused to the L chain and another fused to the Fd chain, or to create a trifunctional molecule by fusing a scFv to one chain and a signalling molecule such as IL2 to another (Figure 10).

Figure 7 shows that Fd:L can efficiently 20 heterodimerize two different scFv molecules.

A) Expression of trispecific antibodies that can target two different tumor antigens. The E6 Fab chains were both extended at their C-terminal side with a scFv molecule. An anti BCL1 tumor marker scFv was fused 25 to the E6L chain using two different linker sequences: L4 and L5 of 6 and 12 amino acid length respectively. These fusion genes were co-expressed with an E6 Fd - 2c11 scFv (anti CD3 scFv) fusion with an interconnecting linker of 20 amino acids (linker H2). The gels show the medium of 30 cells expressing the L-scFv alone or in combination with a non-extended Fd chain or with an Fd-scFv fusion. The arrows indicate the position of the L-scFv fusion monomer and dimer, and of the scFv-L:Fd and scFv-L:Fd-scFv heterodimer. All mouse immunoglobulin products were 35 visualized by probing the blot with goat anti mouse IgG γ/κ . The hPLAP developed blot reveals functional hPLAP binding molecules (only E6 L:Fd associations bind hPLAP). The position of the molecular weight markers is indicated

09625049-072400

on the side of the gel. Both TsAb molecules were efficiently produced.

B] Influence of linker composition and length on the production of trispecific antibody derivatives. An anti (HIS)₆ scFv carrying an E-tag was coupled to the E6 L chain using five different linker sequences, indicated as L4, L5, L6, L7 and L8. This E-tagged (αHIS) scFv-L fusion was combined with a HIS-tagged Fd-scFv (αCD3) and almost exclusively produced scFv-L:Fd-scFv heterodimers as shown by the revelation of the blotted proteins by hPLAP, anti IgG γ/κ, anti E-tag and anti HIS-tag. The position of the TsAb and of the molecular weight markers is shown on the side of the gel. All linker combinations gave equal expression levels of the TsAb.

C] In an analogous way, the L-chain with TL8, L4, L5, L6 and L7 linked αHISscFv could be heterodimerized with the Fd chain with a H1 coupled αCB3scFv. Especially important is the efficient expression of the L-(L8)-scFv with the Fd-(H1)-scFv, since both linkers are relatively short.

Figure 8 demonstrates the functionality of the trispecific antibody derivatives.

The TsAb (αhPLAP x α BCL1 x αCD3) with the L4 linker was produced to monitor its binding specificities and functionality.

A] All three encoded binding specificities are functional. The TsAb was shown to bind at (1) BCL1 B-cell lymphoma cells (BCL1*), (2) MO4I4 fibrosarcoma cells (hPLAP*) and (3) to the TE2 T-cell line (CD3*). Binding was detected by goat anti mouse serum γ/κ followed by an incubation with FITC-coupled anti goat serum.

B] The trispecific antibody derivative is able to bind two different molecules at the same time. While one antigen was fixed on a support (a cell membrane or plastic), a second specificity was used to detect the binding. The TsAb was bound to (1) MO₄I₄ (hPLAP*) cells or (2) to TE2 T-cells, and subsequently incubated with biotinylated BCL1 IgM antibody (BCL1 is an idiotypic

antigen) and FITC-coupled streptavidin. In a third setup BCL1 IgM was coated on MaxiSorb (Nunc) ELISA plates and detected by revealing the bound hPLAP (3). A (ahPLAP x ahPLAP x α CD3) antibody of the same configuration but lacking the α BCL1 specificity was used as a negative control. Blanco values were obtained by incubation with the detection antibodies alone (both with FACScan analysis and with ELISA experiments).

C] The trispecific antibody derivatives can cross-link two different cell markers. The TsAb (ahPLAP x α BCL1 x α CD3) was able to act as efficiently as a BsAb in a T-cell proliferation assay with M04I4 (hPLAP*) cells and in an assay with BCL1 lymphoma cells as targets. This proves that the molecule acts as a bispecific antibody on both the (ahPLAP x CD3) and the (α BCL1 x α CD3) axes. In this assay, both the TsAb with the L4 and the L5 linkers connecting the α BCL1 scFv to the L chain were compared.

(1) T-cell proliferation of Balb/c spleen cells upon cocultivation with mitomycin treated BCL1^{vitro} cells in the presence of the trispecific antibody with linker 4 (TsAb (L4), or with linker 5 TsBab (L5). The linker length between the α CD3 and α BCL1 scFv and the Fab as no influence on the bridging capacity of the trispecific antibody.

(2) T-cell proliferation of C3H spleen cells upon cocultivation with mitomycin treated M04I4 cells in the presence of the trispecific antibody with linker 4 TsAb (L4) or with linker 5 TsBab (L5). The control B1Fab-sFb bispecific molecule does not induce T-cell proliferation. The linker length between the α BCL1 scFv and the Fab has no influence on the bridging capacity of the two other specificities in the trispecific antibody.

Figure 9 illustrates the expression of multivalent antibody derivatives. Using the model of extending one or both of the L- or Fd chain of a Fab chain at their C-terminus with scFv molecules can lead to:

A] expression of bivalent T-cell binding bispecific antibody derivatives;

B] expression of bivalent tumor cell binding bispecific antibody derivatives; and

5 C] expression of trivalent tumor cell binding monospecific antibody derivatives. 10% non-reducing SDS gels were blotted and developed with goat anti mouse IgG γ/κ followed by alkaline phosphatase coupled anti goat and NBT/BCIP staining, except when indicated that a hPLAP
10 staining was performed. The FACScan-analysis was performed with the same antibodies, except the last detection antibody was a FITC-coupled anti goat serum. The position of the various antibody forms produced and of the molecular weight markers is shown at the side of
15 the gels. All derivatives were produced in HEK293T cells by transient co-transformation of vectors expressing the indicated L-chain or Fd-chain fusion proteins. The linker sequences used fuse the scFv to the L or the Fd chain are indicated as L2, L4, L5, L6, L7, H2, H6 and H7 with
20 single code amino acid sequences. The chains for which the expression vectors were co-transfected are drawn on top of the lanes.

In figure 10 the expression of multifunctional antibody derivatives is shown. The L:Fd interaction can
25 be used to heterodimerize molecules of different classes. Here, fusion molecules of IL2 with both the L- or the Fd-chain were successfully expressed. This could even be accomplished when using a 3 amino acid linker for fusing to the L chain (L61), combined with a 6 amino acid linker
30 for fusing to the Fd-chain (H61). The position of the fusion products after non-reducing 10% SDS-PAGE was revealed after protein blotting and immunodetection and is indicated beside the gel, as well as the position of the molecular weight markers run on the gel.

35 Different combinations of native L- and Fd-chains were co-expressed with complementary chains that were extended at their C-terminus with murine IL2 molecules or with a scFv molecule. Native L:Fd chains

09625049 072400
were combined (lane 1), as well as L:Fd-(H61)-mIL2 (lane 2), L:Fd-(H62)-mIL2 (lane 3), L-(L61)-mIL2:Fd-(H61)-mIL2 (lane 4), L-(62)-mIL2:Fd-(H62)-mIL2 (lane 5) and L-(L4)- α BCL1scFv:Fd-(L62)-mIL2 (lane 6). The first gel was
5 developed with hPLAP, gels 2 and 3 were developed with goat anti mouse IgG γ/κ followed by alkaline phosphatase coupled anti goat and NBT/BCIP staining.

This example shows that also signaling molecules (which can be different or alike) can be
10 dimerized by the L:Fd interaction, without loss of binding activity of the reconstituted Fab fragment. Also molecules belonging to different molecular classes, such as signaling molecules and scFv molecules, can be heterodimerized by the L:Fd interaction.

15

In summary, the present invention relates to a class of molecules specified as novel multipurpose antibody derivatives. This class of molecules is created by heterodimerization of two constituting components.

20 Heterodimerization is obtained by the specific heterotypic interaction of a chosen VH-CH1 combination of immunoglobulin domains, with a chosen VL-CL combination of immunoglobulin domains. The VHCH1-VLCL interaction is proposed as a very efficient heterodimerization scaffold
25 that could be efficiently produced. By choosing the appropriate VH and VL domains in the VHCH1 and VLCL context, a binding specificity can be constituted by the heterodimerization scaffold itself. One or both of the comprising VHCH1 and VLCL chains can thus be extended at
30 either the N- or the C-terminus or both with other molecules, for the purpose of combining these molecules with each other.

The other molecules that are genetically coupled to the heterodimerization scaffold with peptide
35 linkers of choice, can be a toxin polypeptide, an enzyme, a hormone, a cytokine, a signaling molecule, or a single chain linked Fv fragment with the same or a different specificity. In this way, combining three or more

different specificities by combining a Fab molecule with a certain specificity with two or more scFv molecules with two or more different specificities can lead to trispecific or multispecific antibodies derivatives while
5 maintaining a lower molecular weight.

Also, the method described allows for the production of bispecific antibodies with a bivalent binding of only one specificity, while maintaining a monovalent binding of the other specificity. In its
10 minimal form, the methods allows for the creation of bispecific antibodies with monovalent binding to each antigen, by combining a specificity encoded by the Fab chains with a single scFv fusion, without the inclusion of a linker sequence derived from an immunoglobulin hinge
15 region.

This format differs from previously described gene-engineered antibody formats by using the intrinsic behavior of the Fab-chain fragments to heterodimerize. One or more extensions can be made at the N- or C-
20 terminal side, but never including a hinge region, which by itself is a homodimerizing motif. By not including the hinge region, it is much simpler to obtain monovalent binding specificities in the molecule.

25

DEPOSIT DATA

The following deposits were made pursuant to rule 28 EPC:

1. pCAGGSE6L (present in E.coli MC1061 cells deposited
30 on October 15, 1997 at the Belgian Coordinated Collection of Microorganisms and given the deposit accession no. LMBP3714)
2. pCA2C11sFvE6Hf (present in E.coli DH5α cells deposited on October 15, 1997 at the Belgian
35 Coordinated Collection of Microorganisms and given the deposit accession no. LMBP3715)
3. pCAE6HfGS2C11sFv (also identified as pCAE6H2sc2C11H) (present in E.coli MC1061 cells deposited on October

15, 1997 at the Belgian Coordinated Collection of Microorganisms and given the deposit accession no. LMBP3716)

5

ABBREVIATIONS

- | | | |
|---------------|---|--|
| Ab | : | antibody |
| BME | : | β-mercaptoethanol |
| BsAb | : | bispecific antibody |
| 10 BssFv | : | bispecific single chain Fv fragment |
| BSA | : | bovine serum albumin |
| BvAb | : | bivalent antibody |
| C- | : | carbon-terminus |
| °C | : | degrees Celsius |
| 15 2C11 | : | from 145-2C11 hamster anti CD3 antibody |
| CD3(ε) | : | cluster of differentiation 3 (ε-chain) |
| CH1, CH3 | : | first and third constant domain of the immunoglobulin heavy chain |
| CL | : | constant domain of the immunoglobulin light chain |
| 20 COS-1 | : | CV-1 cells with defective SV40 origin of replication |
| DNA | : | desoxyribonucleic acid |
| DMEM | : | Dulbecco minimal essential medium |
| 25 EDTA | : | ethylenediaminetetraacetic acid |
| E6 | : | murine monoclonal antibody against hPLAP |
| <u>E.coli</u> | : | Escherichia coli |
| f | : | fragment |
| Fab | : | antigen binding fragment including VL, CL, VH and CH1 |
| 30 Fab' | : | Fab fragment with hinge region |
| FACS | : | Fluorescence activated cell sorter |
| Fc | : | fragment with C-terminal domains of the immunoglobulin heavy chain |
| 35 FCS | : | Foetal calf serum |
| Fd | : | VH-CH1 heavy chain fragment, truncated after CH1 |
| FITC | : | fluorescein isothiocyanate |

	γ	:	Ig heavy chain
	h	:	hours
	H	:	Ig heavy chain
	HEK	:	human embryonic kidney cells
5	hPLAP	:	human placental alkaline phosphatase
	Ig	:	immunoglobulin
	IL2	:	interleukin 2
	IMAC	:	immobilized metal affinity chromatography
	kDa	:	kilodalton
10	κ	:	Ig light chain
	l	:	linker sequence
	L	:	light chain
	LB	:	Luria-Bertani
	LMBP	:	Laboratory of Molecular Biology Plasmid Collection
15	M	:	molar
	min	:	minutes
	mpAb	:	multipurpose antibody
	N-	:	amino-terminus
20	NP-40	:	nonidet-P40
	PAGE	:	polyacrylamide gel electrophoresis
	PBS	:	phosphate buffered saline
	PCR	:	polymerase chain reaction
	rpm	:	revolution(s) per minute
25	SDS	:	sodium dodecyl sulfate
	sec	:	second
	sFv	:	single-chain linked Fv-fragment
	SV40	:	simian virus 40
	TE	:	Tris-EDTA-buffer
30	U	:	unit
	UTR	:	untranslated region
	VH, VL	:	variable domains of the Ig heavy and light chains
	3D5	:	from the scFv 3D5 specific for (His) ₆
35	mIL2	:	mouse interleukin 2
	Bla	:	<u>Escherichia coli</u> Beta-lactamase
	H1-7	:	linker peptide in the heavy chain derived fusion products

0065349-072430

- | | | |
|---------------------|---|---|
| L1-8 | : | linker peptide in the light chain derived fusion products |
| B1 | : | hamster mAb against BCL1 idiotype |
| IDA | : | International Depository Authority |
| 5 | : | LMBP/BCCM Plasmid Collection, K. L. Ledeganckstraat 35, B-9000 Gent |
| CTL | : | cytotoxic T-lymphocyte |
| (Fab') ₂ | : | dimerized Fab' fragments |
| ³ H | : | tritium |
| 10 ⁵¹ Cr | : | radioactive chromium |
| α | : | anti |
| CBB | : | Coomassie Brilliant Blue |
| VH2 | : | VH domain derived from the second antibody |
| VL2 | : | VL domain derived from the second antibody |
| 15 VH3 | : | VH domain derived from the third antibody |
| VL3 | : | VL domain derived from the third antibody |

REFERENCES

- Carter P., Kelley R. F., Rodrigues M. L., Snedecor B., Covarrubias M., Velligan M. D., Wong W. L. T.,
5 Rowland A. M., Kotts C. E., Carver M. E., Yang M.,
Bourell J. H., Shepard H. M. and Hennes D. (1992) High
level *Escherichia coli* expression and production of a
bivalent humanized antibody fragment. *Bio/Technology* 10,
163-167.
- 10 Cheung S. C., Dietzschold B., Koprowski H., Notkins
A. L. and Rando R. F. (1992) A recombinant human Fab
expressed in *Escherichia coli* neutralizes Rabies virus.
J. Virol. 66(11), 3714-6720.
- Choe, M., Webber K.O. & Pastan I. (1994) - B3(Fab) -
15 PE38M : a recombinant immunotoxin in which a mutant form
of *Pseudomonas* exotoxin is fused to the Fab fragment of
monoclonal antibody B3. *Cancer Res* 54 (13), 3460-3467
- Coloma M. J. and Morrison, S. L. (1997) Design and
production of novel tetravalent bispecific antibodies.
20 *Nat. Biotech.* 15, 159-163.
- De Jonge J., Brissinck J., Heirman, C., Demanet C.,
Leo O., Moser M. and Thielemans K. (1995) Production and
characterization of bispecific single-chain antibody
fragments. *Mol. Immunol.* 17(18), 1405-1412.
- 25 De Sutter K., Feys V., Van de Voorde A. and Fiers W.
(1992a) Production of functionally active murine and
murine:human chimeric F(ab')₂ fragments in COS-1 cells.
Gene 113, 223-230.
- De Sutter K., Remaut E., & Fiers, W. (1992b)
30 Disulphide bridge formation in the periplasm of *E.coli*: β -
lactamase: Human IgG3 hinge fusion as a model system.
Mol. Microbiol. 6, 2201-2208.
- De Waele P., Feys V., Van de Voorde A., Molemans F.
and Fiers W. (1988) Expression in non-lymphoid cells of
35 mouse recombinant immunoglobulin directed against the
tumor marker human placental alkaline phosphatase. *Eur.*
J. Biochem. 176, 287-295.

00625049-672400

- DuBridge R. B., Tang P., Hsia H. C., Leong P-M., Miller J. H. and Calos M. P. (1987) Analysis of mutations in human cells by using an Epstein-Barr virus shuttle system. *Mol. Cell. Biol.* **7**, 379-387.
- 5 Ducancel F., Gillet D., Carrier A., Lajeunesse E., Ménez A. & Boulain J.C. (1993) - Recombinant colorimetric antibodies : construction and characterization of a bifunctional F(ab)2/Alkaline Phosphatase conjugate produced in *Escherichia coli*. *Bio/Technology* **11**, 601-605
- 10 Flamez D., Remaut E. and Fiers W. (1995) Production in *Escherichia coli* of a functional murine and murine::human F(ab')2 fragment and mature antibody directed against human placental alkaline phosphatase. *J. Biotechnol.* **42**, 133-143.
- 15 Grooten J. and Fiers W. (1989) Acquisition by the murine host of responsiveness towards various neoplastic cell lines, but not towards self, through adoptive transfer of a helper T lymphocyte clone with anti self specificity. *Cancer Res.* **49**(14), 3872-3878.
- 20 Hendrix P. G., Dauwe S.E., Van de Voorde A., Nouwen E. J., Hoylaerts M. F. and De Broe M. (1991) Radiolocalisation and imaging of stably hPLAP-transfected MO₉ tumours with monoclonal antibodies and fragments. *Br. J. Cancer* **64**, 1060-1068.
- 25 Holliger P., Prospero T. and Winter G. (1993) 'Dibodies': Small bivalent and bispecific antibody fragments. *Proc. Nat. Acad. Sci. USA* **90**, 6444-6448.
- Ku S., Shivily L., Raubitschek A., Sherman M., Williams L. E., Wong J. Y. C., Shivily E. J. and Wu A. M. (1996) Minibody: A Novel engineered anti carcino-embryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid high-level targeting of xenografts. *Cancer Res.* **56**, 3055-3061.
- Huylebroeck D., Maertens G., Verhoeven M., Lopez C., 35 Raeymakers A., Min Jou W. and Fiers W. (1988) High-level transient expression of influenza virus proteins from a series of SV40 late and early replacement vectors. *Gene* **66**, 163-181.

- Jost C. R., Kurucz I., Jacobus C. M., Titus J. A., George A. J. T. and Segal D. M. (1994) Mammalian expression and secretion of functional Single-Chain Fv molecules. *J. Biol. Chem.* **269**(42), 26267-26273.
- 5 **Knappick, A. & Plückthun, A. (1994)** An improved affinity tag based on the FLAG peptide for the detection and purification of recombinant antibody fragments. *Biotechniques* **17**(4), 754-761.
- 10 **Laemli U. K. (1970)** Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* **227**, 680-685.
- 15 **Lammerant W., (1994-1995)** Produktie van antilichamen, antilichaamderivaten en recombinante immunotoxines in *Saccharomyces cerevisiae*. Rijksuniversiteit Gent, PhD. Thesis.
- 20 **Leo O., Foo M., Sachs D. H., Samelson L. E. and Bluestone J. A. (1987)** Identification of a monoclonal antibody specific for a murine T3 polypeptide. *Proc. Natl. Acad. Sci. USA* **84**(5), 1374-1378.
- 25 **Mertens, N., Renaut, E. and Fiers, W. (1995)** Versatile, multi-featured plasmids for high-level expression of heterologous genes in *Escherichia coli*: overproduction of human and murine cytokines. *Gene* **164**, 1-15.
- 30 **Niwa H., Yamamura K. and Miyazaki J. (1991)** Efficient selection for high-expression transfectants with a novel eukaryotic vector. *Gene* **108**, 193-200.
- 35 **Ridgway J. B. B., Presta L. G. and Carter P. (1996)** 'Knobs-into-holes' engineering of CH3 domains for heavy chain heterodimerization. *Prot. Eng.* **9**(7), 617-621.
- 40 **Smans K. A., Hoylaerts M. F., Narisawa S., Millán J. L. and De Broe M. E. (1995)** Bispecific antibody-mediated lysis of placental and germ cell alkaline phosphatase targeted solid tumors in immunocompetent mice. *Cancer Res.* **55**, 4383-4390.
- 45 **Ward, E.S.** Expression and purification of antibody fragments using *E. coli* as a host. (1992). In: Antibody

engineering, a practical guide. Editor: C.A.K.
Borrebaeck. Publisher: W.H. Freemant and co, New York.

004220" 64052960

WHAT IS CLAIMED IS:

1. A multipurpose antibody derivative, comprising the CL and VL domains of a first antibody with a desired first antigen binding specificity, wherein said CH1 and VH domains of the said first antibody interact with said CL and VL domains; and one or more other molecules having at least one different purpose coupled to one or more of the domains of said first antibody.
2. The multipurpose antibody derivative of Claim 1, wherein said one or more other molecules are selected from the group consisting of: sFv molecules, toxins, enzymes, hormones, cytokines, and signalling molecules.
3. The multipurpose antibody derivative of Claim 1, wherein at least two other molecules having at least one further purpose are coupled to one or more of the domains of said first antibody.
4. The multipurpose antibody derivative of Claim 1, wherein the coupling of one or more of the domains of the first antibody to the other molecule(s) is via a linker.
5. The multipurpose antibody derivative of Claim 4, wherein said linker is an amino acid chain of at least 1 amino acid.
6. The multipurpose antibody derivative of Claim 4, wherein said linker is an amino acid chain of at least 3 amino acids.
7. The multipurpose antibody derivative of Claim 1, wherein the other molecule(s) is/are coupled to a molecule selected from the group consisting of:
 - the N-terminus of the VH domain of the first antibody;
 - the C-terminus of the CH1 domain of the first antibody;
 - the N-terminus of the VL domain of the first antibody;
 - the C-terminus of the CL domain of the first antibody, and more than one of the above.
8. The multipurpose antibody derivative of Claim 2, wherein said first antibody is directed against human placental alkaline phosphatase (hPLAP) and said sFv consists of the VL and VH domains of the antimurine CD3 ϵ antibody 2C11.
9. The multipurpose antibody derivative of Claim 8, wherein the VL domain of the 2C11 antibody is fused at its C-terminus to the VH domain of the

2C11 antibody via a linker and the VH domain of the 2C11 antibody is fused at its C-terminus to the N-terminus of the VH domain of the E6 antibody, which is fused at its C-terminus to the N-terminus of the CH1 domain of the E6 antibody.

10. The multipurpose antibody derivative of Claim 8, wherein said VH
5 domain of the 2C11 antibody is fused at its N-terminus to the C-terminus of the VL domain of the 2C11 antibody via a linker sequence and said VL domain is fused at its N-terminus to the C-terminus of the CH1 domain of the E6 antibody via a linker sequence.

11. The multipurpose antibody of Claim 8, wherein the VL domain of the
10 2C11 antibody is fused at its N-terminus to the C-terminus of the VH domain of the 2C11 antibody via a linker sequence and the VH domain is fused at its N-terminus to the C-terminus of the CH1 domain of the E6 antibody via a linker sequence having the amino acid sequence EPSGP (G₄S)₄M.

12. A method for the treatment of cancer, infections, parasites,
15 autoimmune diseases, thrombosis, comprising;

administering the multipurpose antibody derivative of Claim 1 in an amount effective for reducing the number of cancer cells, infectious agents, and parasites.

13. A diagnostic kit comprising:
20 the antibody of Claim 1.

14. A vector encoding the heavy domain containing chains of a multipurpose antibody comprising: suitable transcription and translation regulatory sequences operably linked to sequences encoding the VH and CH1 domains of a first antibody

25 15. The vector of Claim 14 further comprising, a coding sequence for the other molecule operably linked thereto.

16. The vector of Claim 15, wherein said coding sequence for the other molecule comprises DNA sequences encoding the VL and VH domains of a second antibody, wherein said DNA sequences are operably linked to each other as 5'-
30 VL2L-VH2-3' or 5'-VH2-VL2-3'.

17. The vector of Claim 15, wherein a linker sequence is incorporated between one or more of the DNA sequences selected from the group consisting of:

VH, CH1, VL2, VH2 coding sequences, and the coding sequence for the other molecule.

18. The vector of Claim 14, wherein said vector is pCA2C11sFvE6Hf deposited under the Belgian Coordinated Collection of Microorganisms accession no. LMBP3715.

19. The vector of Claim 14, wherein said vector is pCAE6HfGS2C11sFv (also identified as pCAE6H2sc2C11H) deposited under the Belgian Coordinated Collection of Microorganisms accession no. LMBP3716.

20. A vector encoding the light domain containing chains of a multipurpose antibody, comprising: suitable transcription and translation regulatory sequences operably linked to sequences encoding the VL and CL domains of a first antibody.

21. The vector of Claim 20 further comprising a coding sequence for the other molecule operably linked thereto.

22. The vector of Claim 21, wherein said coding sequence for the other molecule comprises DNA sequences encoding the VL and VH domains of a second antibody, wherein said DNA sequences are operably linked to each other as 5'-VL2-VH2-3' or 5'-VH2-VL2-3'.

23. The vector of Claim 21, wherein a linker sequence is incorporated between one or more DNA sequences selected from the group consisting of: VL, CL, VL2, VH2 coding sequences, and the coding sequence of the other molecule.

24. A set of DNA constructs for producing multipurpose antibody derivatives, comprising the vector of Claim 14 together with a construct encoding at least the light domains VL and CL of a first antibody.

25. A set of DNA constructs for producing multipurpose antibody derivatives, comprising the construct of Claim 20 together with a construct encoding at least the heavy domains VH and CH of a first antibody.

26. The set of Claim 21, comprising vector pCAE6HfGS2C11 and vector pSV51E6L.

27. The set of Claim 21, comprising vector pCa2C11sFvE6Hf and vector pSV51E6L.

28. A host cell comprising the set of Claim 21.

29. A method for producing the multipurpose antibody derivatives of Claim 1 comprising expressing a set of vectors in heterologous host cells.

30. The method of Claim 29, wherein the host cells are selected from the group consisting of: bacteria, fungi, and mammalian cells.

5 31. The method of Claim 30, wherein the bacterial cells are selected from the group consisting of: actinomycetes, *E. coli*, *Bacillus* spp., *Lactobacillus* spp. and *Lactococcus* spp.

32. The method of Claim 30 wherein said fungi are filamentous fungi or yeast.

10 33. The method of Claim 30 wherein said mammalian cells are selected from the group consisting of: COS-1 cells, HEK cells, and insect cells.

34. The method of Claim 29 wherein said antibody derivatives are produced in transgenic animals or plants

15 35. A medicament for the treatment of cancer comprising the multipurpose antibody derivative of Claim 1 in an amount effective to decrease the number of cancer cells.

36. A medicament for the treatment of infections comprising the multipurpose antibody derivative of Claim 1 in an amount effective to reduce the infection.

20 37. A medicament for the treatment of parasites comprising the multipurpose antibody derivative of Claim 1 in an amount effective to decrease the number of parasites.

38. A medicament for the treatment of autoimmune diseases comprising the multipurpose antibody derivative of Claim 1 in an amount effective to decrease the symptoms of said autoimmune disease.

39. A medicament for the treatment of thrombosis comprising the multipurpose antibody derivative of Claim 1 in an amount effective to decrease the thrombosis.

30 40. The diagnostic kit of claim 13 wherein said kit is used to diagnose any disease selected from the group consisting of: cancer, infections, parasites, autoimmune diseases, and thrombosis.

MULTIPURPOSE ANTIBODY DERIVATIVESAbstract of the Disclosure

The present invention relates to a class of molecules specified as novel multipurpose antibody derivatives. This class of molecules is created by heterodimerization of two constituting components. Heterodimerization is obtained by the specific heterotypic interaction of a chosen VH-CH1 combination of immunoglobulin domains, with a chosen VL-CL combination of immunoglobulin domains. The appropriate VH and VL domains in the VHCH1 and VLCL context, a binding specificity can be constituted by the heterodimerization scaffold itself. One or both of the comprising VHCH1 and VLCL chains can thus be extended at either the N- or the C-terminus or both with other molecules, such as a toxin polypeptide, an enzyme, a hormone, a cytokine, a signaling molecule, or a single chain linked Fv fragment with the same or a different specificity.

FIGURE 1






FIGURE 2




3/14

FIGURE 3A



4/14

FIGURE 3B



5/14

FIGURE 4A





FIGURE 4B

T-cell proliferation assay:
tritium thymidin incorporation



CTL mediated, BsAb dependent tumor lysis:
⁵¹Cr-release assay




FIGURE 5A




FIGURE 5B




FIGURE 6A






FIGURE 6B




8/14

FIGURE 7A




9/14

FIGURE 7B




10/14

FIGURE 7C




11/14

FIGURE 8



12/14

FIGURE 9A



13/14

FIGURE 9B




FIGURE 9C





FIGURE 10



DECLARATION - USA PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled MULTIPURPOSE ANTIBODY DERIVATIVES; the specification of which is attached hereto;

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above;

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56;

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below, and insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56, which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Prior U.S.A. Application(s)

Application No.: **PCT/EP99/00477** Filing Date: **January 25, 1999** Status: **Pending**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful, false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor: **Reinhilde Schoonjans**

Inventor's signature _____

Date July 14, 2000

Residence: **Kerkstraat 25, B-9850 Landegem, BELGIUM**

Citizenship: **Belgium**

Post Office Address: **Same as Above**

Full name of second inventor: **Nico Mertens**

Inventor's signature 

Date July 14, 2000

Residence: **Pauwstraat 58, B-9120 Melsele, BELGIUM**

Citizenship: **Belgium**

Post Office Address: **Same as Above**

Full name of third inventor: **Walter Fliers**

Inventor's signature 

Date July 14, 2000

Residence: **Beukendreef 3, B-9070 Destelbergen, BELGIUM**

Citizenship: **Belgium**

Post Office Address: **Same as Above**

Full name of fourth inventor: **Roland Contreras**

Inventor's signature 

Date July 14, 2000

Residence: **Molenstraat 53, B-9820 Schelderode-Merelbeke, BELGIUM**

Citizenship: **Belgium**

Post Office Address: **Same as Above**

Send Correspondence To:

KNOBBE, MARTENS, OLSON & BEAR, LLP

Customer No. 20,995

H:\DOCS\JAH\JAH-2871.DOC:bb062800

004220.6402260

SEQUENCE LISTING

<110> Vlaams Interuniversitair Instituut voor Biotechnol

<120> Multipurpose antibody derivatives

<130> VIB-009-PCT

<140> PCT/EP99/00477

<141> 1999-01-25

<150> 98200193.5

<151> 1998-01-23

<160> 46

<170> PatentIn Ver. 2.1

<210> 1

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 1

ccgtctcctc agagctccaa aaaccc

26

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 2

cactgccgag ctcccaaac

20

<210> 3

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 3

tcatgtcgcg gccgcgctct a

21

<210> 4

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:AMINO ACID

LINKER

<400> 4

Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val

1

5

10

<210> 5

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 5

ggcccatgga ggtcaagctg gtggagtc

28

<210> 6

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 6

ataccatcct tatccggacc ttttatttcc agcttggtgc cag

43

<210> 7

<211> 21

<212> DNA

CCDS:300226.1

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 7

gctgaaaggg cccggtggag g

21

<210> 8

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 8

ggtcccaggg cactggcctc actctagag

29

<210> 9

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 9

cagtgagcag ttaacatctg g

21

<210> 10

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 10

cccttggggc ccacactcat tcc

23

<210> 11

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 11

gctgaaaggg cccggtggag g

21

<210> 12

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 12

gtgccagggc actggttaag atctggatcc

30

<210> 13

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 13

cctcacctcg agtgatcagc actg

24

<210> 14

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 14

ccacctgagg agacagtgac c

21

<210> 15

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 15

ctgcctcctc aggcaaaaca acaccc

26

<210> 16

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 16

ggacccagtg catgccatag cc

22

<210> 17

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 17

ggatgtcaca ttgtgatgac c

21

<210> 18

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 18

gatacctttga gctccagc

18

<210> 19

<211> 20

<212> DNA

004220-492592

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 19

gttggagctc aaacgggctg

20

<210> 20

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 20

ggagctgggtg gtggcgtctc aggacc

26

<210> 21

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 21

ataccgctcg agacacagac atgagtgtgc ccactc

36

<210> 22

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 22

ataccgctcg agacacagac atgagtgtgc ccactc

36

<210> 23

<211> 31

<212> DNA

001219 6405295

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 23

tcccccgggg aagtgaagct ggtggagtct g

31

<210> 24

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 24

ataggatcct tatccggatt tcagctccag cttggtccca gc

42

<210> 25

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 25

tcccccgggc aggttcagct gcagcagtct ggag

34

<210> 26

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 26

ataggatcct tatccggacc gttttatttc cagcttggtc c

41

<210> 27

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 27

cgacggtggt tctagaggtg atgggc

26

<210> 28

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 28

ccgggcccac cacctctaga accacggtcg acgt

34

<210> 29

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 29

ggcctcaacc acaacctcag ccgcaacctc aacctgggc

39

<210> 30

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 30

ccgggcccag gttgaggttg cggctgaggt tgtggttga

39

<210> 31

<211> 39

<212> DNA

03625649-072406

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 31

ggcctcaacc acaacctcag ccgcaacctc aacctgggc

39

<210> 32

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 32

ccgggccag gttgagggtg cggtgaggt tgtggttga

39

<210> 33

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 33

tccccgggg acattttcat gacccaaact ccac

34

<210> 34

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:OLIGONUCLEOTIDE

<400> 34

ataggatcct tatccggatt cgcccccca ggcvcgcaga gacag

45

<210> 35

<211> 57

<212> DNA

3955049-57246

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: OLIGONUCLEOTIDE

<400> 35

tccggagcgc cggtgccgta tccagatccg ctggaaccac gtggcgccta aggatcc 57

<210> 36

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AMINO ACID
LINKER

<400> 36

Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Leu
1 5 10 15

<210> 37

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AMINO ACID
LINKER

<400> 37

Glu Pro Ser Gly
1

<210> 38

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AMINO ACID
LINKER

SEQUENCE OF THE

<400> 38

Glu Pro Ser Gly Pro Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
1 5 10 15

Gly Gly Gly Ser Met
20

<210> 39

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AMINO ACID
LINKER

<400> 39

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Met
1 5 10 15

<210> 40

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AMINO ACID
LINKER

<400> 40

Asp Val Pro Gly
1

<210> 41

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AMINO ACID
LINKER

001218-040336

<210> 45
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: AMINO ACID
LINKER

<400> 45
Glu Pro Ser Gly Pro Pro Ser Pro Gly
1 5

<210> 46
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: AMINO ACID
LINKER

<400> 46
Glu Pro Ser Gly Pro Met
1 5